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JUDITH F. DAAR* 
I.  INTRODUCTION 
Advances in reproductive medicine are notorious for yielding previously 
unthinkable methods of enhancing human procreation, alongside equally 
unanticipated ethical and social dilemmas. The introduction of 
preimplantation genetic diagnosis (PGD) produced such dual consequences 
and continues to challenge traditional notions of health and medical 
decision-making.  PGD is a medical technique originally developed in 
England in the late 1980s as a method of detecting single-gene disorders in 
unimplanted three-day old embryos.1  The basic PGD procedure involves 
the creation of embryos via in vitro fertilization (IVF), followed by the 
extraction via biopsy of a single cell, known as a blastomere, from the three-
day old, eight-celled embryo.2  Because each blastomere is totipotent in the 
early embryo—meaning it has “all potential” and can develop into a 
separate, wholly intact new embryo—studying this single cell reveals the 
genetic make-up of the embryo from which it was taken.3  PGD can detect 
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Law School.  I am grateful to Elizabeth Pendo for inviting me to participate in the 2008 Saint 
Louis University School of Law Health Law Symposium.  Heartfelt gratitude is also extended to 
Russell Korobkin, Taimie Bryant, and Robert Goldstein from UCLA School of Law for vetting a 
condensed version of this piece.  Finally, I want to thank David Smolin for including me in the 
February 2008 symposium sponsored by the Center for Biotechnology, Law, and Ethics at 
Cumberland Law School at Samford University, where I presented an earlier version of this 
paper. 
 1. A.H. Handyside et al., Biopsy of Human Preimplantation Embryos and Sexing by DNA 
Amplification, LANCET, Feb. 18, 1989, at 347, 348; KRISTINE BARLOW-STEWART & MONA SALEH, 
CENTRE FOR GENETICS EDUCATION, FACT SHEET 18, at 1 (2007), available at 
www.genetics.edu.au/pdf/factsheets/fs18.pdf (last visited Feb. 3, 2009). 
 2. See AUDREY HUANG, GENETICS & PUB. POL’Y CTR., PREIMPLANTATION GENETIC 
DIAGNOSIS (2006), available at www.dnapolicy.org/images/issuebriefpdfs/PGD_Issue_ 
Brief.pdf (last visited Feb. 3, 2009); Handyside et al., supra note 1. 
 3. According to Dr. Machelle M. Seibel, “Preimplantation genetic diagnosis (PGD) is 
very much like an amniocentesis performed after fertilization but before the pregnancy is 
implanted.  IVF is performed, and the embryo is allowed to divide up to at least four cells and 
usually up to eight cells.  A small hole is made in the zona pellucida and one or two cells of 
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whether an embryo is genetically normal, or whether it expresses a genetic 
anomaly associated with a disease or disorder.4 
Because of its role in assisted conception, PGD joins the sundry medical 
techniques under the rubric “assisted reproductive technologies” (ART).  
PGD’s initial usage was limited to prospective parents anxious to birth a 
child unaffected by a genetic disorder that had plagued the family’s lineage 
for generations.5  Inevitably, interest in surveying the genetic make-up of 
early embryos grew to encompass clinical scenarios likely not contemplated 
by the technique’s originators.6  In addition to screening to discover the 
genetic health of the conceptus, today ART physicians can use PGD to 
screen embryos so that, if later born alive, the resulting children’s blood, 
organs, or tissues can be used to support the health of another person, 
often a whole blood sibling.7  An even more recent use of PGD is the 
selection of embryos based on parental preferences for offspring whose 
sensory or mobility capabilities reflect that of their genetic parent or 
 
the embryo are removed, fixed on a slide and analyzed by molecular biology testing. The 
molecular biology tools used to perform PGD are either polymerase chain reaction (PCR), 
which is a method that amplifies a single gene defect so that it can be seen on a gel 
electrophoresis, or fluorescent in situ hybridization (FISH), which stains a particular piece of 
DNA with a fluorescent color that can be seen using a special microscope.  The diagnosis is 
made within a few days, and the unaffected embryos are then transferred into the mother's 
uterus so that pregnancy can occur.”  AMY BERLIN COOK ET AL., ADOPTION AND REPRODUCTIVE 
TECHNOLOGY LAW IN MASSACHUSETTS §9.7 (Susan L. Crockin ed., 2000); Ashley Bumgarner, 
Note, A Right to Choose?: Sex Selection in the International Context, 14 DUKE J. GENDER L. & 
POL’Y 1289, 1294 (2007). 
 4. PGD is used to detect two types of genetic anomalies: (1) inherited chromosomal 
abnormalities in which a gene or portion of a gene contains a mutation, causing such 
disorders as Tay-Sachs disease, Duchene muscular dystrophy, cystic fibrosis, and Huntington’s 
disease, or (2) sporatic (non-inherited) aneuploidy, in which the genome contains either too 
few or too many chromosome in one or more of the 23 pairs.  See HUANG, supra note 2 
(discussing aneuploidy and inherited genetic disorders).  Some of the more well-known 
disorders associated with aneuploidy include Down syndrome (also known as “Trisomy 21,” or 
three chromosomes in 21st pair), Edwards syndrome (Trisomy 18), Patau syndrome (Trisomy 
13) and Klinefelter syndrome (XXY, having an extra “X” sex chromosome).  See NAT’L HUM. 
GENOME RESEARCH INST., CHROMOSOME ANALYSIS (2005), available at www.genome.gov/ 
Pages/Education/Modules/ChromosomeAnalysis.pdf (last visited Feb. 3, 2009) (discussing 
chromosomal disorders). 
 5. See Susannah Baruch et al., Genetic Testing of Embryos: Practices and Perspectives 
of U.S. In Vitro Fertilization Clinics, 89 FERTILITY & STERILITY 1053, 1053 (2008). 
 6. See, e.g., id. at 1055 (though PGD was developed to screen unborn children for 
genetic disorders, today PGD can be used to select the sex of an embryo “to satisfy the 
preferences of the future parents.”). 
 7. Id.; Bill Radford, The Designer Baby: Right or Wrong?, BALTIMORE SUN, Jan. 14, 
2001, at 1N. 
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parents.8  The following true-life stories explain each of three PGD 
scenarios. 
Vignette 1: Using PGD for the Health of the Embryo.  Chicago resident 
Chad Kingsbury suffered the loss of his mother, maternal grandfather, and 
two maternal uncles from an inherited form of colon cancer.9  As a carrier of 
the genetic mutation associated with familial susceptibility to the adult-onset 
disease, Chad was terrified that his children would inherit his predisposition 
to colon cancer.10  For the Kingsburys, PGD “offered them a way to reload 
the genetic dice.”11  The couple joined a growing pool of prospective 
parents with heritable cancer-susceptibility genes who turned to ART to 
assure the birth of a child free of the family genetic mutation.12  In addition 
to colon cancer susceptibility, PGD can now be used to screen for other 
genetically-based adult-onset diseases including Huntington’s disease, 
Alzheimer disease, and breast cancer.13  While the Kingsburys took months 
to make the decision to use PGD, the result was a child free of the colon 
cancer gene.14  While talking to reporters about his child’s conception, 
Chad Kinsbury gazed at daughter Chloe and remarked, “I couldn’t imagine 
them telling me my daughter has cancer . . . when I could have stopped 
it.”15 
Vignette 2: Using PGD for the Health of Another Person.  By 1999, Lisa 
and Jack Nash’s five-year old daughter Molly was nearing death from 
Fanconi’s anemia, an inherited genetic disorder that leads to bone marrow 
failure and early forms of cancer.16  Her only hope for recovery was a 
compatible stem cell donor, but exhaustive searches within her family and 
her community failed to produce a suitable donor.17  The Nashes consulted 
Yuri Verlinsky, director of the Reproductive Genetics Institute in Chicago, 
 
 8. Liza Mundy, A World of Their Own, WASH. POST, Mar. 31, 2002 (Magazine), at 22. 
 9. Amy Harmon, Couples Cull Embryos to Halt Heritage of Cancer, N.Y. TIMES, Sept. 3, 
2006, at A1. (reporting that “one in every 200 Americans carry a genetic mutation that makes 
them susceptible to breast or colon cancer.”). 
 10. Id. 
 11. Id. at A20. 
 12. Id. 
 13. A recent survey reveals that twenty-eight percent of ART “clinics have provided PGD to 
avoid an adult-onset disease such as Huntington disease, hereditary breast cancer, or 
Alzheimer disease.”  Baruch et al., supra note 5, at 1055. 
 14. Harmon, supra note 9, at A20. 
 15. Id. 
 16. See Dan Vergano, Custom Baby Saves a Life, USA TODAY, Jan. 8, 2001, at 7D; 
Radford, supra note 7; Deborah Josefson, Couple Select Healthy Embryo to Provide Stem 
Cells for Sister, 321 BRIT. MED. J., 917, 917 (2000). 
 17. Radford, supra note 7, at 9N; Liza Acevedo, Stem Cell Siblings, SCIENCENTRAL, Sept. 
9, 2004, at www.sciencentral.com/articles/view.php3?article_id=218392351&cat=3_2 (last 
visited Feb. 3, 2009). 
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who pioneered the technique of testing embryos for genes that make 
antigens—structures that determine whether tissues will be compatible with a 
transplant recipient.18  Using IVF and PGD, physicians were able to identify 
which of the Nashes’ embryos were both free of the Fanconi’s anemia gene 
and a tissue match for Molly.19  On August 29, 2000, the family welcomed 
Adam, a healthy child whose umbilical cord blood was prepared for transfer 
into Molly.20  Within a few months, Molly had regained much of her strength 
and thereafter went on to make near full recovery.21 
Vignette 3: Using PGD to Satisfy Parental Preferences.  Long-time 
partners Sharon Duchesneau and Candace McCullough wanted a child that 
resembled them in one important way.22  The couple was deaf, and their 
idea of the perfect child was one who could move in and appreciate the 
deaf culture that was defining for the prospective parents.23  The women 
inquired of the local sperm bank, only to learn that deafness is a 
disqualifying trait for sperm donors; thus no suitable sperm was available in 
the marketplace.24  Determined to maximize the chances their child would 
be deaf, they turned to a deaf friend who agreed to serve as a sperm 
donor.25  Six years later, the couple were parents to a daughter and a son, 
both deaf.26  Though Sharon and Candace’s journey to parenthood did not 
involve the use of PGD (which can detect genetic deafness), their story 
prompted researchers to ask whether physicians would be willing to provide 
the technique to cull embryos for certain genetic anomalies.27  A survey 
published in 2006 indicates that at least a few IVF centers have assisted in 
selecting for a “disability” such as deafness or dwarfism.28 
 
 18. Radford, supra note 7, at 9N; Acevedo, supra note 17; Scott Gottlieb, Scientists 
Screen Embryo for Genetic Predisposition to Cancer, 322 BRIT. MED. J. 1505, 1505 (2001). 
 19. See Gottlieb, supra note 18. 
 20. See Josefson, supra note 16. 
 21. Radford, supra note 7; Cable News Network, Health, Genetic Selection Gives Girl a 
Brother and a Second Chance, Oct. 3, 2000, at http://archives.cnn.com/2000/HEALTH/10/ 
03/testube.brother/ (last visited Nov. 21, 2008) (having received a transplant from sibling, 
Molly now has an eighty-five percent chance survival rate; Molly will not recover fully and will 
continue experiencing other symptoms of the disease throughout her lifetime). 
 22. See Mundy, supra note 8, at 24; Darshak M. Sanghavi, Wanting Babies Like 
Themselves, Some Parents Choose Genetic Defects, N.Y. TIMES, Dec. 5, 2006, at F5. 
 23. See Mundy, supra note 8, at 25. 
 24. See id. at 24. 
 25. See id. 
 26. See id. at 26. 
 27. See Sanghavi, supra note 22. 
 28. Baruch et al., supra note 5, at 1055 (noting that “[t]hree percent of IVF-PGD clinics 
report having provided PGD to couples who seek to use PGD to select an embryo for the 
presence of a [disease or] disability.”). 
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The availability and use of PGD layers a social choice atop a medical 
decision.  Parents who choose to implant only those embryos that offer 
compatible tissue for an ailing child simultaneously make the decision to 
discard or defer development of otherwise healthy embryos because they 
lack utility for an immediate purpose.  Parents whose family trees are dotted 
with relatives devastated by certain genetically-based diseases must decide 
in the earliest moments of conception whether to eliminate embryos that 
bear the mutation, or entrust the health of their offspring to the uncertainty 
of future medical advances.  Parents with sensory or other deficits who 
desire a similarly-abled child may discard genetically healthy embryos in 
pursuit of their vision of the perfect child.  Each of these scenarios calls into 
question traditional notions of health, disability and reproductive choice. 
Part II of this article chronicles the use of PGD and other reproductive 
technologies from their inception to current practices, observing that each 
advance has produced some unintended consequence.  The ability to mesh 
human gametes in the laboratory, form embryos, freeze embryos for later 
use, and cull embryonic cells for their rich genetic story has been essential to 
family formation.  Yet these advances have simultaneously introduced 
conflicts and harms that were unimaginable in a pre-ART world.  Part II 
briefly surveys a few of the inadvertent consequences wrought by a staple in 
the ART arsenal—IVF.  Examples include genetic parenthood after divorce, 
after death, and even after learning that one’s embryos were mistakenly 
transferred to another patient with an overlapping clinic appointment.  The 
law can and has responded to these scenarios with familiar tools borrowed 
from family law, tort law, contract law, and other sources.  PGD, as the 
newest reproductive technology, can draw upon some of the same 
disciplines when mishaps occur, but the unintended consequences of 
embryonic genetics are more subtle and arguably more globally 
problematic. 
Part III of this article surveys the use of PGD as described in Vignette 1—
to assess embryonic health as a means of birthing a child free of known 
genetic anomalies.29  At least three conundrums emerge when parents 
 
 29. Vignettes 2 and 3, using PGD for the health of another, and for the preferences of the 
parents, are not treated in depth herein, though each scenario has generated robust 
discussion in the legal literature.  For discussion on genetic enhancement and engineering, as 
well as issues arising from the use of PGD see, for example, Kirsten Rabe Smolensky, Creating 
Children with Disabilities: Parental Tort Liability for Preimplantation Genetic Interventions, 60 
HASTINGS L.J. 299 (2008); Dov Fox, Silver Spoons and Golden Genes: Genetic Engineering 
and the Egalitarian Ethos, 33 AM. J. LAW & MED. 567 (2007); Michele Goodwin, My Sister’s 
Keeper?: Law, Children, and Compelled Donation, 29 W. NEW ENG. L. REV. 357 (2007); 
Donna M. Gitter, Am I My Brother’s Keeper?  The Use of Preimplantation Genetic Diagnosis to 
Create a Donor of Transplantable Stem Cells for an Older Sibling Suffering from a Generic 
Disorder, 13 GEO. MASON L. REV. 975 (2006); Lindsey A. Vacco, Comment, Preimplantation 
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attempt to orchestrate the implantation of a genetically healthy child.  First, 
there is what I’ll call “the spectrum problem.”  PGD can detect whether the 
offspring will be likely or even certain to express symptoms of the identified 
condition, but it often cannot determine the severity of such manifestation.30  
Moreover, as we increasingly recognize the genetic basis of human health, 
we are able to detect propensity for diseases that will not manifest until the 
fourth or fifth decade of life.  Distinguishing between childhood and adult-
onset diseases, as well as between severe, mild, and benign conditions, is 
both morally and medically difficult in the context of adjusting access to 
genetic technologies.  This essay offers an assessment tool, in the form of a 
multi-factorial questionnaire with assigned point values for each response, 
as one response to the spectrum problem.  Fixing values, even crudely, to 
factors such as severity of symptoms and timing of disease onset, may aid in 
understanding the proper uses of PGD to maximize embryo health. 
A second conundrum evoked by PGD is its shifting of responsibility for 
health from person to parent.  Part III describes “the shifting problem,” 
noting that PGD may also shift the way we view health in the future.  A 
parent’s ability to spare a child from a disease for which the parent has a 
genetic susceptibility means that parent and child may act very differently in 
their health-related decisions.  While the parent may make lifestyle choices 
to reduce the risk of disease onset, including the use of therapeutics or even 
prophylactic surgeries, the child will be medically unburdened, possibly 
unprepared to accept anything less than perfect health that could come in 
the form of sporadic disease or traumatic injury.  Additionally, as control 
over health shifts from person to parent, those prospective parents who 
access reproductive technologies (and even those who do not) may come 
under increasing pressure to use PGD to avoid even mild anomalies.  This 
pressure to utilize genetic technologies to avoid all genetic anomalies—
herein labeled “the expectation problem”—represents the third conundrum 
in the trilogy.  Part III discusses the expectation interests that genetic 
technologies raise, focusing on the expectations of prospective parents and 
the society into which their children are born. 
 
Genetic Diagnosis: From Preventing Genetic Disease to Customizing Children. Can the 
Technology Be Regulated Based on the Parents’ Intent?, 49 ST. LOUIS U. L.J. 1181 (2005); 
Susan M. Wolf et al., Using Preimplantation Genetic Diagnosis to Create a Stem Cell Donor: 
Issues, Guidelines & Limits, 31 J. LAW, MED. & ETHICS 327 (2003).  The goal of this article is to 
examine the motivations, expectations, and consequences that can accompany a decision to 
use PGD for the health of the embryo.  It is my hope that these foundational observations will 
inform future discussions about other PGD uses. 
 30. Human Genetics Alert, Response to HFEA Consultation on Sixth Edition of the Code 
of Practice, at www.hgalert.org/topics/geneticSelection/hga_response.htm (last visited Feb. 3, 
2009). 
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Advances in reproductive medicine can evoke the myth of Sisyphus 
pushing his stone up a mountain only to see it roll back as he nears the 
summit.31  In a crude sense, today’s version of the myth pits reproductive 
scientists, who toil to advance the technology surrounding assisted 
conception, against observers who sometimes push back against advances 
that alter the traditional course of reproduction.  The introduction and 
subsequent refinement of PGD display these push-pull qualities, producing 
stunning achievements in reproductive medicine, while instilling enormous 
unease over our newfound ability to manipulate the human genome.  What 
follows are arguments for pushing the nascent science of reprogenic 
medicine up the mountain, and counterarguments for letting it roll right 
back down.  In my view, at the end of the day, unlike Sisyphus, PGD will 
make sustainable and essential progress in advancing human health. 
II.  UNINTENDED CONSEQUENCES IN ART 
Breakthroughs in the nascent field of reproductive medicine have yielded 
a host of unintended consequences.  Since the introduction of IVF in 
1978,32 the technique is credited with the birth of over three million children 
worldwide.33  Combined with other ARTs such as artificial insemination by 
donor, oocyte donation, and surrogate parenting arrangement, IVF gives 
prospective parents increasing choice and control over their reproductive 
futures.  The successful integration of ART into modern society is evident by 
the numbers alone: today, three out of every one hundred children in the 
U.S. are born as a result of some form of assisted conception.34  Moreover, 
 
 31. See ALBERT CAMUS, THE MYTH OF SISYPHUS 5 (Raymond Soulard, Jr. & Kassandra 
Soulard eds., 2006) (1942). 
 32. The world’s first “test tube” baby, Louise Brown, was born outside London on July 25, 
1978.  See Peter Gwynne, All About That Baby, NEWSWEEK, Aug. 7, 1978, at 66, 67.  Louise 
was conceived using IVF, a medical technique in which the egg and sperm are introduced 
under the glare of a laboratory petri dish, instead of in the dark quiet recesses of a woman’s 
fallopian tube.  Id.  Once the sperm fertilizes the egg, the resulting embryo is nurtured in the 
lab for several days and then transferred into a woman’s uterus where it will, hopefully, 
implant and develop until birth.  Id. 
 33. See European Society for Human Reproduction and Embryology; Three Million Babies 
Have Been Born Using Assisted Reproductive Technologies, WOMEN’S HEALTH LAW WKLY., July 
16, 2006, at 77 (referencing a 2006 report by the International Committee for Monitoring 
Assisted Reproductive Technologies estimating the use of one million ART cycles a year, 
producing approximately 200,000 babies worldwide). 
 34. According to an annual report published by the Centers for Disease Control and 
Prevention (CDC), in 2005 (the most recent year for which figures are available) there were 
52,041 children born in the U.S. who were conceived using some form of assisted 
reproductive technology (ART), as defined by the CDC to include only those techniques in 
which both the egg and the sperm are handled.  In 2005, ninety-nine percent of all ART cycles 
measured by the CDC used IVF, with fewer than one percent using the related techniques of 
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the use of ART, particularly IVF, has increased every year since 1995, the 
first year in which such data was collected.35  Though fundamentally 
grounded in medicine, today’s reproductive technologies nimbly navigate 
from petri dish culture to business culture36 to popular culture.37  Yet despite 
 
gamete intrafallopian transfer (in which eggs and sperm are transferred into the fallopian tube) 
and zygote intrafallopian transfer (in which the early embryo is transferred into the fallopian 
tube).  See CTRS. FOR DISEASE CONTROL & PREVENTION, U.S. DEP’T. OF HEALTH & HUM. SERVS., 
2005 ASSISTED REPRODUCTIVE TECHNOLOGY SUCCESS RATES: NATIONAL SUMMARY AND FERTILITY 
CLINIC REPORTS 61, 85 (2007), available at www.cdc.gov/ART/ART2005/508PDF/2005ART 
508.pdf (last visited Feb. 3, 2009) [hereinafter 2005 ART REPORT].  In addition to IVF births, it 
is estimated that 60,000 children are born annually via artificial insemination by donor (AID), 
a technique in which only the sperm is handled (and thus births by AID are not included in the 
annual CDC report).  See Inst. for Sci., Law & Tech. Working Group, ART into Science: 
Regulation of Fertility Techniques, 281 SCIENCE 651 (1998).  Births via IVF and AID bring the 
total number of children born through assisted conception to roughly 110,000; the total birth 
rate for 2005 was slightly over four million.  See CTRS. FOR DISEASE CONTROL & PREVENTION, 
U.S. DEP’T. OF HEALTH & HUM. SERVS., Births: Final Data for 2005, 56 NATIONAL VITAL STATISTICS 
REPORTS, Dec. 5, 2007, 1, at 1, available at www.cdc.gov/nchs/data/nvsr/nvsr54/ 
nvsr54_02.pdf (last visited Feb. 3, 2009) (reporting 4,138,349 live births in the U.S. in 2005, 
up by approximately one percent from 2004).  Thus, total ART births in the U.S. in 2005 
comprised slightly over 2.7% of all live births). 
 35. See 2005 ART REPORT, supra note 34, at 61 (showing ten-year trends in the number 
of ART cycles performed from 1996-2005, as well as the number of live-birth deliveries during 
that same period using ART.  Both ART cycles and deliveries increased by more than double.  
The CDC data on ART trends captures data from 1996 forward, excluding data from 1995 
because it did not include all reporting U.S. ART clinics). 
 36. See Michele Goodwin, Assisted Reproductive Technology and the Double Bind: The 
Illusory Choice of Motherhood, 9 J. GENDER RACE & JUST. 1, 5, 46-49 (2005).  Professor 
Goodwin argues that access to ART creates a “double bind” for women in the workplace, 
especially professional women whose superiors place subtle pressure on younger women to 
defer childbearing to increase their chances of “fair” opportunities at law firms, businesses, or 
university posts.  ART is seen as a technological bail out for women who put off childbearing, 
thus encouraging continued participation in the workplace.  Pregnancy and motherhood 
discrimination, Professor Goodwin argues, are soft but real discrimination that create “double 
binds” for women who believe they must choose between career and early motherhood.  See 
generally id. 
 37. The well-publicized use of IVF and gestational surrogacy by celebrities, as well as 
incorporation of ART into movie and television plots has contributed to its role in popular 
culture.  See, e.g., Celebrities Who Have Used IVF and Surrogacy, Part 2, at http://egg-
donation-directory.blogspot.com/2007/10/celebrities-who-have-used-ivf-and.html (last visited 
Feb. 3, 2009) (listing model and actress Cindy Margolis, actor Chris Meloni, actress Laurie 
Metcalf, and anchorwoman Joan Lunden as patrons of gestational surrogates); BABY MAMA 
(Universal Studios 2008); see also Internet Movie Database, Synopsis for Baby Mama, at 
www.imdb.com/title/tt0871426/synopsis (last visited Feb. 3, 2009); Press Release, Nat’l 
Infertility Ass’n, Internet Icon, Supermodel Cindy Margolis to Serve as National Spokesperson 
for Resolve: The National Infertility Association (June 7, 2005), at www.resolve.org/site/ 
PageServer?pagename=fmed_mcpr20050607 (last visited Feb. 3, 2009).  The hit ABC 
primetime series Ugly Betty included a plot twist involving the use of IVF and surrogacy in early 
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ART’s seemingly seamless adoption as a procreative alternative, its rapidly 
advancing technical prowess has spawned numerous unexpected dilemmas. 
ART’s unintended consequences are best viewed from the perspective of 
its two major purposes—to treat infertility and to promote the health of 
offspring.  Infertility treatment is based on a model in which gametes are 
extracted from the body and melded into embryos, many of which are frozen 
for later use.38  The presence of gametes and embryos outside the body, 
subject to human manipulation, invites scenarios that are only possible in an 
ART world.  In one New York fertility clinic, a white patient became pregnant 
with twin boys, one white and one black, because a laboratory technician 
mixed-up two couples’ embryos on the day of transfer.39  The white couple’s 
“successful” use of ART inadvertently wrought tremendous pain and suffering 
to the black couple whose embryo was negligently misdirected.  After a two-
year legal battle, the black child was ordered returned to his genetic 
parents, but the debacle caused irreparable harm to both sets of parents.40  
This case and others like it disaggregate the roles of race, genetics, and 
gestation in determining parenthood, three factors that had heretofore 
vested in a single individual. 
The freezing of sperm, eggs, and embryos can also produced 
unintended results.  When a happily married couple undergoes IVF and 
freezes excess embryos for future use, they likely do not intend to later 
divorce and squabble bitterly over the disposition of those embryos, but such 
cases abound.41  When a couple agrees to freeze embryos, neither party 
anticipates that the embryos will be released to the other without mutual 
consent, but at least several children have been born after their mothers 
forged their (non-consenting) fathers’ name on the authorizing 
documentation.42  Equally unexpected are decisions about the fate of 
 
2008.  Ugly Betty: A Thousand Words by Friday (ABC television broadcast Jan. 24, 2008); 
see also ABC.com, Ugly Betty Episode Recaps, at http://abc.go.com/primetime/uglybetty/ 
index?pn=index (last visited Feb. 3, 2009). 
 38. See 2005 ART REPORT, supra note 34, at 3, 4. 
 39. Perry-Rogers v. Fasano, 715 N.Y.S. 2d 19, 21-22 (2000). 
 40. Id. at 27; see also IVF Mix-Up Heads for Court, BBC NEWS, July 8, 2002, at 
http://news.bbc.co.uk/2/hi/health/2115522.stm (last visited Feb. 3, 2009) (summarizing 
several cases across Europe and the U.S. in which laboratory mix-ups involving sperm, eggs, 
or embryos have resulted in the birth of offspring). 
 41. See, e.g., Davis v. Davis, 842 S.W.2d 588, 589 (Tenn. 1992); Kass v. Kass, 91 
N.Y.2d 554, 560 (1998); A.Z. v. B.Z., 725 N.E.2d 1051, 1053 (Mass. 2000); J.B. v. M.B., 
783 A.2d 707, 710 (N.J. 2001); In Re Marriage of Witten, 672 N.W.2d 768, 768 (Iowa 
2003) (all involving litigation over the disposition of frozen embryos upon divorce of the 
intended parents). 
 42. See, e.g., Sarah-Kate Templeton, Wife’s Embryo Fraud Makes Estranged Husband a 
Father, SUNDAY TIMES (London), Mar. 2, 2008, at 7, at www.timesonline.co.uk/tol/news/ 
uk/article3466762.ece (last visited Feb. 3, 2009). 
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gametes and embryos after the death of one or more of the intended 
parents.  With sperm and embryo banks willing to keep material in frozen 
storage for decades,43 the phenomenon of posthumous birth—the birth of 
genetic offspring after the death of a genetic parent—will become more 
routine.44 
A final noteworthy unintended consequence of fertility treatment is its 
spillover into the emerging world of embryonic stem cell research.  When 
researchers at the University of Wisconsin announced in the fall of 1998 
they had succeeded in isolating and cultivating stem cells from human 
embryos, ART suddenly developed a second identity as a potential for 
medical cures.45  The Wisconsin stem cell lines were developed from 
embryos donated by couples who had previously undergone IVF for 
reproductive purposes.46  Seeing ART through the fresh lens of stem cell 
research focused attention on questions that were part of the backdrop of 
assisted conception, but had largely escaped the scrutiny that this type of 
research unleashed.  Questions about the moral wisdom and legal authority 
surrounding the intentional destruction of embryos for research purposes, as 
well as the consent necessary to utilize gametes and embryos in medical 
experiments, moved front and center in the minds of stakeholders and 
observers alike.47 
Stem cell research brought public attention to the possible medical 
benefits of ART apart from treating infertility, thus broadening the impact of 
advances in reproductive medicine from personal and procreative to global 
 
 43. On November 1, 2007, a child was born to a forty-three-year old Canadian man 
who had stored sperm prior to chemotherapy in 1985.  The child’s conception using decades 
old thawed sperm, however, was not a record.  “The longest-known storage period of sperm 
resulting in a live birth is 28 years, according to a 2005 report in the American medical 
journal Fertility and Sterility.”  Lena Sin, Baby Conceived with Sperm Frozen Long Ago, at 
www.canada.com/story.html?id=973186 (last visited Feb. 3, 2009). 
 44. Several U.S. courts have already grappled with the question of whether a 
posthumously born child can be considered the heir of their predeceased parent for purposes 
of probate law, with most answering in the affirmative.  See, e.g., In re Gillett-Netting v. 
Barnhart, 371 F.3d 593, 593-94, 599 (9th Cir. 2004) (all finding in favor of heirship for 
posthumously born children); Woodward v. Comm’r of Soc. Sec., 760 N.E.2d 257, 272 
(Mass. 2002); Estate of Kolacy, 753 A.2d 1257, 1258 (N.J. 2000).  But see Khabbaz v. 
Comm’r, Soc. Sec. Admin., 930 A.2d 1180, 1182 (N.H. 2007) (finding child was not a 
“surviving issue” of father under state law). 
 45. See James A. Thomson et al., Embryonic Stem Cell Lines Derived from Human 
Blastocysts, 282 SCIENCE 1145, 1145, 1147 (1998). 
 46. Id. at 1145. 
 47. See generally RUSSELL KOROBKIN & STEPHEN R. MUNZER, STEM CELL CENTURY: LAW & 
POLICY FOR A BREAKTHROUGH TECHNOLOGY (2007) (providing a comprehensive discussion of 
these and other issues surrounding embryonic stem cell research). 
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and life-saving.48  While ART as a medical therapy may have first emerged 
in the public eye with embryonic stem cell research, its origins can be traced 
back to PGD.49  Private individuals with family histories of genetic disorders 
learned decade earlier of reproductive medicine’s ability to address human 
health outside the infertility context.50  PGD made its entrance into medical 
literature in 1990 as a method of detecting lethal genetic anomalies in early 
embryos, but has since expanded to permit reproductive decision-making on 
the basis of speculative health and social criteria.51  Today’s prospective 
parents who access PGD can decide how much genetic health to require of 
their early embryos, a decision with potential consequences far beyond the 
birth of any resulting offspring.52 
III.  THE USE OF PGD TO ASSURE OFFSPRING HEALTH 
The array of genetic disorders and characteristics that PGD can detect 
grows with each passing year.  Currently, PGD is performed for 
approximately one hundred genetic conditions, each carrying a unique 
profile in terms of severity of impact on overall health and onset of somatic 
symptoms.53  Some of the detected conditions are fatal in the first years of 
life, such as Tay-Sachs disease; others pose serious health risks and often 
cause death in early adulthood, such as cystic fibrosis and Huntington’s 
disease; still others are associated with an increased predisposition to adult-
onset diseases such as colon and breast cancer.54  The ability to access this 
vast array of genetic information, only some of which is reliably predictive of 
disease, enables prospective parents to decide what is, and is not, an 
acceptable level of health for their future children. 
This power to orchestrate offspring health, however, is rife with problems 
of imprecision.  Just as geneticists are unable to predict the severity of 
certain conditions, parents are likewise unable to predict the impact these 
health choices will have on their offspring, on themselves, and on society at 
large.  What follows is an effort to isolate, describe, and analyze the 
 
 48. See Sarah Franklin, Embryonic Economies: The Double Reproductive Value of Stem 
Cells, 1 BIOSOCIETIES 71, 71, 80 (2006) (discussing the influence of IVF on stem cell 
research). 
 49. See Carl T. Hall, Stem Cell Research May Be Boon to Fertility Clinics, S.F. CHRON., 
Feb. 21, 2005, at A6. 
 50. See Howard W. Jones, Jr. & Jean Cohen, Chapter 14: Preimplantation Genetic 
Diagnosis, 87 FERTILITY & STERILITY (Supplement 1) S47, S47 (2007). 
 51. Id. at S47, S49. 
 52. Id. 
 53. See HUANG, supra note 2. 
 54. See Baruch et al., supra note 5, at 1054; Press Release, Human Fertilisation & 
Embryology Authority, HFEA Licenses PGD for Inherited Colon Cancer (Nov. 1 2004), at 
www.hfea.gov.uk/en/1049.html (last visited Feb. 3, 2009). 
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variables associated with the use of PGD to detect embryo health.  For ease 
of reference, I categorize the variables into three areas which I’ll label “the 
spectrum problem,” “the shifting problem,” and “the expectation problem.” 
A. The Spectrum Problem 
If medicine is an art, then medical genetics may be best described as 
abstract expressionism for its break from the traditions of the past in a 
manner that can be jarring and incomprehensible.  But as any fan of Willem 
de Kooning will croon, the vibrancy and energy of his colorful abstract 
canvases helped pave the way for a new generation of artists.55  Likewise 
medical genetics breaks from the diagnostic practices of the past, offering 
predictions and prophylaxis long before any symptoms present.  Our current 
understanding of genetics provides clarity with respect to certain disease 
processes, while remaining frustratingly out of focus for a host of other 
genetic anomalies.  Questions of when, whether, and how severely a 
disease will manifest embody the spectrum problem. 
PGD can detect whether a resulting child’s genome will contain a 
genetic anomaly associated with a particular disease, but often it cannot 
predict how the disease will be expressed during the child’s life.56  For 
example, both Down syndrome and cystic fibrosis can be detected through 
PGD, but to date there is no clinical measure for the severity of symptoms 
associated with the diseases.  According to the National Institutes of Health, 
“Down syndrome symptoms vary from person to person and can range from 
mild to severe.”57  The National Down Syndrome Congress concurs, adding 
that “[t]here is wide variation in mental abilities, behavior and physical 
development in individuals with Down syndrome.  Each individual has 
his/her own unique personality, capabilities and talents.”58  The Cystic 
Fibrosis Foundation likewise advises that the course of cystic fibrosis varies 
 
 55. For information about Willem de Kooning, see Guggenheim Collection, Artist - de 
Kooning - Biography, at www.guggenheimcollection.org/site/artist_bio_36.html (last visited 
Feb. 3, 2009). 
 56. PGD remains susceptible to human and laboratory error, and misdiagnosis is a 
clinical reality.  See, e.g., Y. Verlinsky et al., Accuracy and Outcomes of 3631 Preimplantation 
Genetic Diagnosis (PGD) Cycles Performed in One Center, 84 FERTILITY & STERILITY 
(Supplement 1) S98 (2005) (reporting misdiagnosis in PGD, resulting in an accuracy rate of 
99.5%). 
 57. U.S. NAT’L LIBRARY OF MEDICINE & NAT’L INST. OF HEALTH, MEDICAL ENCYCLOPEDIA: 
DOWN SYNDROME, at www.nlm.nih.gov/medlineplus/ency/article/000997.htm (last visited 
Feb. 3, 2009). 
 58. Nat’l Down Syndrome Congress (NDSC), Facts About Down Syndrome, at 
www.ndsccenter.org/resources/package3.php (last visited Feb. 3, 2009). 
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from person to person.59  Symptoms such as lung infections and coughing 
can be mild or severe.60  On a hopeful note, the Foundation reports that the 
predicted median age of survival of a cystic fibrosis patient rose to 36.5 
years in 2008, up from 32 years in 2000.61 
Genetic diseases can also vary in terms of the phase in life in which they 
manifest.  While diseases such as Tay-Sachs62 and Fanconi’s anemia63 
manifest at or near birth, other disorders such as Alzheimer disease64 and 
Huntington’s disease65 may not become clinically noticeable until 
adulthood.  Still other PGD-detectible genetic anomalies are associated with 
disease susceptibility, as opposed to disease certainty.66  For example, 
families in which many individuals have been diagnosed with breast or 
colon cancer may share a genetic mutation that increases an affected 
individual’s chances of developing the disease in adulthood.67  Women who 
 
 59. See Cystic Fibrosis Found., Frequently Asked Questions, at www.cff.org/AboutCF/ 
Faqs/ (last visited Feb. 3, 2009). 
 60. See id. 
 61. See id. 
 62. According to the National Institute of Neurologic Disorders and Stroke, “[e]ven with 
the best of care, children with Tay-Sachs disease usually die by age 4, from recurring 
infection.”  Nat’l. Inst. of Neurological Disorders and Stroke, Nat’l Inst. of Health, NINDS Tay-
Sachs Disease Information Page, at www.ninds.nih.gov/disorders/taysachs/taysachs.htm (last 
visited Feb. 3, 2009). 
 63. Fanconi’s amenia is a form of inherited anemia that leads to bone marrow failure.  
See Fanconi Anemia Research Fund, Diagnosis, at www.fanconi.org/aboutfa/Diagnosis.htm 
(last visited Feb. 3, 2009).  Fanconi’s anemia usually reveals itself before children are twelve 
years old, with symptoms such as skeletal anomalies, kidney problems, and blood 
abnormalities.  Id. 
 64. While most forms of Alzheimer’s disease are thought to be sporadic, a small 
percentage are considered familial.  Inherited Alzheimer disease is associated with earlier 
onset of symptoms, sometimes as soon as age thirty-five, compared to the average age of sixty 
for other forms of the disease.  See Found. for Genomics & Population Health, IVF Embryos to 
Undergo Screening for Early-Onset Alzheimer’s Disease (Oct. 1, 2007), at www.phg 
foundation.org/news/3778/ (last visited  Feb. 3, 2009); ALZHEIMER’S DISEASE EDUC. & REFERRAL 
CTR., NAT’L INST. ON AGING, NAT’L INST. OF HEALTH, FACT SHEET: ALZHEIMER’S DISEASE, at 1, 
available at www.nia.nih.gov/NR/rdonlyres/7DCA00DB-1362-4755-9E87-96DF669EAE20/ 
11209/84206ADEARFactsheetAlzDiseaseFINAL08DEC23.pdf (last visited Feb. 3, 2009). 
 65. Huntington’s disease is a “hereditary, degenerative brain disorder for which there is, 
at present, no effective treatment or cure.”  Huntington’s Disease Soc’y of America, What is 
Huntington’s Disease (HD), at www.hdsa.org/about/our-mission/what-is-hd.html (last visited 
Feb. 3, 2009).  According to the Huntington’s Disease Society of America, “HD typically 
begins in mid-life, between the ages of 30 and 50, though onset may occur as early as the 
age of 2. Children who develop the juvenile form of the disease rarely live to adulthood.”  Id. 
 66. See HUANG, supra note 2. 
 67. NAT’L CANCER INST., NAT’L INST. OF HEALTH, FACT SHEET: GENETIC TESTING FOR BRCA1 
AND BRCA2: IT’S YOUR CHOICE at 1-2 (2002), available at www.cancer.gov/images/ 
Documents/abcb7812-a132-4e78-a532-f002c92fa9b9/fs3_62.pdf (last visited Feb. 3, 
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possess the gene mutation associated with the inherited form of breast 
cancer are three to seven times more likely to develop the disease than 
women without the genetic mutation.68  Individuals with certain forms of 
inherited colon cancer are highly likely, but not absolutely certain, to 
develop the disease before the age of fifty.69  Calculating the likelihood of 
disease expression—referred to as “penetrance”70—is further complicated 
by the availability of prophylactic surgery.  In some cases, the onset of 
cancer may be avoided by removing the susceptible organs and tissues from 
the body. 
These spectra of symptoms, time of onset, penetrance, and availability 
of treatment or prophylaxis create challenges for promulgating a monolithic 
view on the use of PGD to screen for embryo health.  That said, absolutist 
views have been expressed.  PGD is prohibited in several countries71 and is 
opposed by the Catholic Church, which teaches that all embryos “ought 
always to be born from an act of love and should already be treated as a 
person.”72  The basis for PGD, the creation of extracorporeal embryos using 
IVF, is a per se violation of the Catholic requirement that embryonic life 
result only from heterosexual intercourse.73  To add clarity to this rejection of 
PGD, in March of 2008 the Church added certain “destructive bioethics 
practices” to its list of mortal sins, including “experiments that manipulate 
DNA or harm embryos”.74  While PGD itself was not named as a specific 
 
2009) [hereinafter NAT’L CANCER INST., BRCA1 AND BRCA2 FACT SHEET]; see American Cancer 
Soc’y, Heredity and Cancer, at www.cancer.org/docroot/CRI/content/CRI_2_6x_Heredity_ 
and_Cancer.asp (last visited Feb. 3, 2009) [hereinafter ACS, Heredity and Cancer]. 
 68. NAT’L CANCER INST., BRCA1 AND BRCA2 FACT SHEET, supra note 67, at 1. 
 69. See ACS, Heredity and Cancer, supra note 67. 
 70. The penetrance of a genetic anomaly is defined as “the probability that the genotype 
will be reflected in the phenotype and will have consequences for health.”  Guido de Wert & 
Joep P.M. Geraedts, Preimplantation Genetic Diagnosis for Hereditary Disorders that Do Not 
Show a Simple Mendelian Pattern: An Ethical Exploration, in CONTEMPORARY ETHICAL DILEMMAS 
IN ASSISTED REPRODUCTION 85, 88 (Françoise Shenfield & Claude Sureau eds., 2006). 
 71. PGD is prohibited by law in Germany, Italy, and Switzerland.  Jones & Cohen, supra 
note 50. 
 72. See Address of His Holiness Benedict XVI to the Participants in the Plenary Assembly of 
the Pontifical Council for the Family (May 13, 2006), at www.vatican.va/holy_father/ 
benedict_xvi/speeches/2006/may/documents/hf_ben-xvi_spe_20060513_pc-family_en.html 
(last visited Feb. 3, 2009). 
 73. See, e.g., Address of His Holiness Pius XII to the Second World Congress in Naples 
on Human Reproduction and Sterility (May 19, 1956). 
 74. Steven Ertelt, Catholic Church Says Abortion, Cloning, Embryo Destruction Are Sinful 
Practices, LIFENEWS.COM, (Mar. 10, 2008), at www.lifenews.com/int652.html (last visited Feb. 
3, 2009). 
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sin, its requisite extraction of embryonic DNA could be interpreted as both 
manipulative and harmful to embryos.75 
In December of 2008 the Church updated its absolutist position on ART 
in the “Instruction on Dignitas Personae on Certain Bioethical Questions.”76  
This Instruction, issued in response to the development of “new biomedical 
technologies,” specifically addressed PGD and declared that the procedure 
“constitutes an act of abortion” because it “is directed toward the qualitative 
selection and consequent destruction of embryos.”77  The Church 
categorized PGD as an 
expression of a eugenic mentality that ‘accepts selective abortion in order to 
prevent the birth of children affected by various types of anomalies.  Such 
an attitude is shameful and utterly reprehensible, since it presumes to 
measure the value of a human life only within the parameters of “normality” 
and physical well-being, thus opening the way to legitimizing infanticide and 
euthanasia as well.’78 
Absolutist views in favor of PGD for medical screening of embryos have 
also appeared.79  At least two subsets of absolutism co-exist in the ethics 
literature on the subject of prenatal genetic technologies.80  One subset 
advocates that prospective parents have a positive moral duty to use genetic 
technologies to enhance the well-being of their offspring, enabling them to 
live longer, run faster, think clearer, and so on.81  A second subset frames 
the positive duty in terms of preventing foreseeable medical harm to children 
by selecting against embryos that bear a known genetic anomaly.82  The 
former subset is perhaps best represented by John Harris, a Professor of 
Bioethics at the University of Manchester, who argues in his recent book that 
 
 75. Id.  The issue of physical harm to the long-term health of the embryo has been 
studied, and recent reports indicate that PGD does not negatively affect embryo health and 
development. See Jeanine Cieslak-Janzen et al., Multiple Micromanipulations for 
Preimplantation Genetic Diagnosis Do Not Affect Embryo Development to the Blastocyst Stage, 
85 FERTILITY & STERILITY 1826, 1828 (2006). 
 76. The Holy See, Congregation for the Doctrine of the Faith, Instruction, Dignitas 
Personae on Certain Bioethical Questions, at www.vatican.va/roman_curia/congregations/ 
cfaith/documents/rc_con_cfaith_doc_20081208_dignitas-personae_en.html (last visited Feb. 
3, 2009). 
 77. Id. 
 78. Id. (citing John Paul II, Encyclical Letter Evangelium Vitae (Mar. 25, 1995), at 
www.vatican.va/holy_father/john_paul_ii/encyclicals/documents/hf_jp-ii_enc_25031995_ 
evangelium-vitae_en.htm) (last visited Feb. 3, 2009). 
 79. See John Harris, Getting Better All the Time, 122 NEW HUMANIST, Nov/Dec 2007, at 
20, 20; see also ALLEN BUCHANAN ET AL., FROM CHANCE TO CHOICE: GENETICS AND JUSTICE 18-
19 passim (2000). 
 80. See Harris, supra note 79, at 20-21; see BUCHANAN ET AL., supra note 79. 
 81. See Harris, supra note 79, at 20-21. 
 82. See BUCHANAN ET AL, supra note 79, at 156. 
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“it is not only feasible to use genetic technology to make people more 
healthy, intelligent and longer-lived, it’s our moral duty to do so.”83  Harris 
considers that “[t]he denial of beneficial enhancements to others, whether 
they are our children or strangers, would be a breach of two of the most 
powerful moral principles, the duty to do good and the duty not to harm; 
whereas the consequences of that denial would leave someone more 
vulnerable to harm and less able to lead a healthy, fulfilling life.”84  These 
outcomes, Harris argues, support a positive moral duty to utilize genetic 
enhancements, including PGD.85 
The latter absolutist approach, which favors a positive duty to prevent 
offspring harm (but not necessarily a duty to enhance an otherwise healthy 
individual), is adopted by philosophers Allen Buchanan, Dan Brock, 
Norman Daniels, and Daniel Wikler in their book, From Chance to Choice: 
Genetics and Justice.86  These esteemed moral and political philosophers 
debate the uses of genetic screening technologies and enhancements, 
concluding “that both justice and our obligations to prevent harm make 
genetic interventions to prevent disabilities not only permissible but also 
obligatory.”87  Absolutist views that PGD must be used by prospective 
parents—either to maximally enhance their offspring’s physical and mental 
attributes, or to prevent known genetically-based disabilities—dismiss the 
spectrum problem as irrelevant.  As long as the child could experience some 
deficit as a result of a genetic anomaly, the moral balance weighs in favor 
of PGD use and embryo selection.  Absolutist views that PGD must never be 
used are likewise refractory to the spectrum problem.  Since respect for 
embryos is the central feature of this position, no degree of disability would 
justify screening or discarding early human life.88 
 
 83. Harris, supra note 79, at 20.  Professor Harris’ book, ENHANCING EVOLUTION: THE 
ETHICAL CASE FOR MAKING PEOPLE BETTER “champions the possibility of influencing the very 
course of evolution to give us increased mental and physical powers—from reasoning, 
concentration, and memory to strength, stamina, and reaction speed.  Indeed, he supports 
enhancing ourselves in almost any way we desire.  And it's not only morally defensible to 
enhance ourselves, Harris says. In some cases, it's morally obligatory.”  Princeton Univ. Press, 
Harris, J.: Enhancing Evolution: The Ethical Case for Making Better People, at 
http://press.princeton.edu/titles/8480.html (last visited Feb. 3, 2009). 
 84. Harris, supra note 79, at 21. 
 85. Id. 
 86. BUCHANAN ET AL., supra note 79, 156-257 (discussing implications of “Genetic 
Perfection” and the duty to prevent harm). 
 87. Id. at 302. 
 88. While absolutist views have been expressed on the use of PGD, numerous middle 
ground positions pepper the debate over the use of PGD.  See generally NICHOLAS AGAR, 
LIBERAL EUGENICS: IN DEFENCE OF HUMAN ENHANCEMENT (2004) (explaining that some 
commentators take the view that parents should have autonomy to utilize available 
technologies to determine what is in the best interest of their future children—but they should 
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Adopting an absolutist view toward the use of PGD for medical 
screening has the benefit of nullifying the spectrum problem.  If one is 
always in favor of or always against PGD, then the clinical realities of 
particular genetic disorders will hold no sway over the absolutist’s position.  
But if one is open to weighing the merits of PGD on a case-by-case basis, or 
along some multi-factorial algorithm, then it would be useful to marshal the 
various points along the spectra identified with genetic disease.  Such an 
algorithm could be used to identify the instances when the use of PGD is 
most acceptable, such as to avoid transmission of fatal childhood disorder, 
or when its use is more questionable, such as when the genetic anomaly has 
low penetrance and produces mild, treatable symptoms in the later decades 
of life. 
Table 1 provides a tool for the numeric assessment of the merits of PGD 
for embryo health screening.  The Table sets out four factors that determine 
the clinical significance of a given genetic anomaly—severity of disease, 
onset of disease, penetrance of disease, and availability of treatment or 
prophylaxis—together with three points along the spectrum for each factor.  
Using a point allocation system, basic parameters for the non-absolutist 
position on PGD can be set out.  The strongest cases mark the end points.  
For example, lethal Tay-Sachs disease would fall in the “should be 
permitted” category, while a (as of now theoretical) mutation that poses a 5 
percent likelihood of causing color blindness in late adulthood would 
represent the “should be discouraged” category.  The majority of cases 
would fall somewhere in between the end points, in the neutral “can be 
permitted” arena.  Even in these cases, it may be possible to more 
definitively resolve the question of whether PGD offers greater benefit than 
 
not be compelled to do so.  Coined “liberal eugenics,” this discipline respects the voluntary 
choices of parents to use genetic techniques that will benefit the child in some way).  Authors 
Guido de Wert and Joep P.M. Geraedts assert that two philosopher scholars—Carson Strong 
and Bonnie Steinbock—have espoused support for open access to PGD for prospective 
parents striving to assure maximal health for their offspring.  Carson Strong urges adoption of 
a medical model in which physicians are “non-directive” toward parental requests for PGD, 
meaning they offer unconditional support for this reasonable request for service.  See de Wert 
& Geraedts, supra note 70, at 87-88 (citing CARSON STRONG, ETHICS IN REPRODUCTIVE AND 
PERINATAL MEDICINE: A NEW FRAMEWORK 180 (1997)).  Steinbock adopts a reproductive 
freedom framework, urging that a woman’s right to control her reproductive life includes the 
right to access information that she deems relevant to any procreative decision.  While doctors 
can discuss concerns about the use of PGD in certain situations, ultimately the decision rests 
with the patient.  Id. at 87 (citing BONNIE STEINBOCK, PREIMPLANTATION GENETIC DIAGNOSIS 
AND EMBRYO SELECTION, A COMPANION TO GENETICS 147-57 in A COMPANION TO GENETHICS 
(C. Burley & J. Harris eds., 2002)). 
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harm.89  A disease that is fatal, or highly debilitating may rank as PGD-
worthy even if its penetrance is low or it is an adult-onset disorder. 
Casting the spectrum problem as a mathematical equation will do little 
to solve the ethical conundrums that PGD poses for non-absolutists, but 
organizing the data in a uniform manner can create a template for debate.  
While the factors included may not be exhaustive, and the spectrum points 
can invite wild speculation about unknowable clinical phenomena, a 
numeric approach does provide a means of assessing the relative merits of 
individual cases.  In an era in which PGD tends to be accessed only by 
those with the means to pay its approximately $15,000 price tag,90 
questions about whether it should be made available are suppressed by 
prevailing market forces in which supply capably meets demands.  Should 
PGD become more widely available through expanded health insurance 
coverage, or even government mandates to provide, a rubric for comparing 
essential and nonessential uses of PGD will be invaluable. 
 
 89. Admittedly, the terms “benefit” and “harm” are ill-defined in this context.  Benefit 
could be measured by parental happiness wrought by the ability to control reproductive 
choice, or by offspring genetic health.  Harm may refer to the risk of damage to or loss of 
embryos attributable to the PGD process, or to the morbidity associated with IVF in general.  
Moreover, balancing benefits and harms pays homage to a utilitarian calculus, in which 
actions are judged ethically acceptable when they produce greater benefits than harms 
overall. 
 90. See Barbara Collura, Nat’l Infertility Ass’n, The Costs of Infertility Treatment, at 
www.resolve.org/site/PageServer?pagename=lrn_mta_cost (last visited Feb. 3, 2009). 
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a = 1, b = 2, c = 3. 
Assessing Outcomes by Total Points: 
4-6  PGD avoid serious harm and should be permitted 
7-9  PGD avoids some harm and can be permitted  
10-12 PGD poses more risk than benefit and should be discouraged 
B. The Shifting Problem 
A parent’s ability to select for or against certain genetic traits in offspring 
challenges the way we have historically viewed health in our society.  
Shifting control and responsibility for health status from person to parent 
could fundamentally change the way future generations view health risks, 
altering their behavior toward themselves and others.  What follows is a 
discussion of the current landscape of health perspectives and its possible 
shift in light of emerging genetic technologies. 
1. The Person-Public Dichotomy 
Our current world view of health tends to vest responsibility for its 
maintenance in two actors: person and public.91  From the person 
 
 91. See BUCHANAN ET AL., supra note 79, at 11-12 (discussing the two perspectives for 
viewing genetic intervention, the “public health model” and the “personal choice model,” 
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perspective, an adult individual enjoys the benefits of maintaining, or suffers 
the consequences of neglecting, bodily and mental functions that generally 
comprise human health.92  A child’s health is likewise subject to a person-
affecting model, with parents or guardians imbued with decision-making 
authority over offspring and minor charges.93  While environmental, familial, 
social, and a host of other factors impact on a person’s health, the person-
affecting model dominates contemporary American constructs of health care 
decision-making.  So essential is the right of the person to control his or her 
health and health care that the principle of patient autonomy sits at the 
nadir of contemporary bioethics.94  Autonomous decision-making about 
individual health is of such moment in our culture that it currently occupies 
the highest echelon of constitutional protection—a right protected against 
government interference under the liberty interest of the Due Process Clause 
of the Fourteenth Amendment to the U.S. Constitution.95  Individual rights 
and responsibilities largely drive health decision-making in the U.S.96 
While the person may be supreme, the public health model also 
occupies a significant role in directing health in our society.  Aided by early 
recognition of the need for public health measures in modern society,97 
 
Buchanan writes that the public health model “stresses the production of benefits and the 
avoidance of harms for groups[,]” while the personal choice model is based upon on 
“individual autonomy.”). 
 92. See id. at 12. 
 93. See id. at 13. 
 94. See generally TOM L. BEAUCHAMP & JAMES F. CHILDRESS, PRINCIPLES OF BIOMEDICAL 
ETHICS 99-148 (6th ed. 2008) (1979) (discussing the connection between patient autonomy 
and health care decision-making). 
 95. Cruzan v. Dir., Mo. Dep’t of Health, 497 U.S. 261, 278 (1990) (writing for the 
majority, Justice Rehnquist acknowledges, “[t]he principle that a competent person has a 
constitutionally protected liberty interest in refusing unwanted medical treatment may be 
inferred from our prior decisions.”).  The question of whether the right to refuse medical 
treatment is a fundamental right is unanswered by the Cruzan majority, though commentators 
have posited that because the Court did not use strict scrutiny or expressly say that there was a 
fundamental right, no such right arose in the case.  E.g., Erwin Chemerinsky, In Defense of 
Roe and Professor Tribe, 42 TULSA L. REV. 833, 833 (2007).  In the Cruzan dissent, Justice 
Brennan, joined by Justices Marshall and Blackmun, said that there is a “fundamental right to 
be free of unwanted artificial nutrition and hydration[.]”  Cruzan, 497 U.S. at 302.  As to a 
protected right to consent to medical care, the Court cited to an oft-quoted early twentieth 
century New York Court of Appeals decision, in which Justice Cardozo observed, “‘[e]very 
human being of adult years and sound mind has a right to determine what shall be done with 
his own body[.]’”  Id. at 269 (quoting Schloendorff v. Soc’y of N.Y. Hosp., 105 N.E. 92, 93 
(1914). 
 96. See Candace Cummins Gauthier, The Virtue of Moral Responsibility in Healthcare 
Decisionmaking, 11 CAMBRIDGE Q. OF HEALTHCARE ETHICS 273, 273-75 (2002). 
 97. See Jacobson v. Massachusetts, 197 U.S. 11 (1905).  In upholding a compulsory 
vaccination law as a valid exercise of the state’s police power, the Jacobson Court 
acknowledged the right of an individual to assert supremacy over the government, but also 
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those currently responsible for protecting the public’s health play an 
essential role in charting the course for human health.  In a sense, public 
health principles act as a filter through which individual decisions about 
health pass, permitting a broader view of the impact that person-affecting 
conduct has on society at large.98  Focusing on population rather than 
person, the public health perspective aims to maximize health for the many, 
even if it means sacrificing the rights of a few.99 
In an era of reproductive genetics in general, and PGD in particular, 
applying the person-public dichotomy yields two distinct views of the value 
of preimplantation embryo selection.  As discussed supra, Philosophers Allen 
Buchanan, Dan Brock, Norman Daniels, and Daniel Wikler describe the 
dual perspectives from which embryonic genetic intervention can be viewed 
as the “public health model” and the “personal choice model.”100  The 
public health model relies on “simple and unqualified consequentialist 
reasoning” and “looks only to the aggregate balance of good over bad.”101  
If PGD, or any genetic intervention, produces an overall benefit for society 
(for example, by the birthing of fewer babies with genetic diseases), then the 
technique would be assessed as ethically sound. 
The utilitarian calculus embedded in the public health model is laudable 
for its ease of use, but is often subject to criticism for its failure to recognize 
the rights, needs, and harms to individuals. Viewing genetic technologies 
from a utilitarian perspective is particularly nettlesome given the devastation 
wrought by the early 20th century American eugenics movement.102  
“Eugenicists believed that most social problems were caused by hereditary 
faults of those afflicted by the problem, and they sought to eventually 
eliminate these problems from society through selective breeding.”103  Using 
a combination of law and social pressure, American eugenicists convinced 
many that society’s greater good would be served by sacrificing the 
 
stated, “it is equally true that in every well-ordered society charged with the duty of conserving 
the safety of its members the rights of the individual in respect of his liberty may at times, 
under the pressure of great dangers, be subjected to such restraint, to be enforced by 
reasonable regulations, as the safety of the general public may demand.”  Id. at 29. 
 98. See id. at 38-39 (holding a state’s interest in protecting its citizens may at times 
override individual rights). 
 99. See BUCHANAN ET AL., supra note 79, at 11. 
 100. Id. 
 101. Id. 
 102. See, e.g., DANIEL J. KEVLES, IN THE NAME OF EUGENICS: GENETICS AND THE USES OF 
HUMAN HEREDITY 46-48 (1985); PAUL A. LOMBARDO, THREE GENERATIONS, NO IMBECILES: 
EUGENICS, THE SUPREME COURT AND BUCK V. BELL 104, 116 (2008); Alexandra Minna Stern, 
Sterilized in the Name of Public Health, 95 AM. J. PUB. HEALTH 1128, 1131-32 (2005). 
 103. Lisa Powell, Note, Eugenics and Equality: Does the Constitution Allow Policies 
Designed to Discourage Reproduction Among Disfavored Groups?, 20 YALE L. & POL’Y REV. 
481, 483 (2002). 
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reproductive rights of a few.104  The eugenics legacy continues to linger as a 
cautionary note to the application of a public health model to advances in 
reprogenic medicine.105 
The personal service model of genetic technologies, according to 
Buchanan and his colleagues, protects private choice as an exercise of 
individual autonomy.106  Parents would be free to use PGD, or to decline to 
use PGD, as a matter of personal choice irrespective of the consequences to 
others.107  The philosophers critique the personal service model for its 
elevation of autonomy over all other values, and thereby its potential to 
subordinate the autonomy of offspring to that of their parents.108  Despite 
these criticisms, the use of PGD in the U.S. today most closely resembles the 
personal service model: its availability is based upon a parent’s ability to 
pay and a provider’s willingness to supply.109 
2. From Person to Parent 
The longstanding person-public perspectives on health are well-suited to 
a construct in which medical decisions affect the well-being of an existing 
individual, but they display signs of obsolescence when health choices are 
made on behalf of future generations.  The use of PGD allows parents to 
wrest control over the health status of their offspring from nature itself.  
Moreover, by taking this prenatal control over offspring health, parents can 
now make health-related decisions that would heretofore have been made 
by the individual—the person whose health is at issue.  Thus, PGD shifts 
responsibility for basic health status from person to parent, adding a third 
lens through which to view the choices and behaviors surrounding health.  
Shifting responsibility for health-related decision-making from person to 
parent can alter the actions of both person and parent. 
In the health paradigm in which an individual’s actions can affect the 
well-being of that person’s mind or body, the individual is incentivized to act 
 
 104. See id. at 483-484 (quoting HARRY H. LAUGHLIN, EUGENICAL STERILIZATION IN THE 
UNITED STATES, A REPORT OF THE PSYCHOPATHIC LABORATORY OF THE MUNICIPAL COURT OF 
CHICAGO 446-47 (1922)).  “Between 1900 and 1963, at least 60,000 Americans were 
sterilized pursuant to eugenic sterilization laws” passed in more than thirty states.  Id. “In 
response to a lawsuit in 1974 the federal government adopted regulations banning 
sterilization without consent in hospitals that receive federal funds, but reports of violations 
surface periodically.”  Id. at 484. 
 105. See, e.g., Michael J. Malinowski, Choosing the Genetic Makeup of Children: Our 
Eugenics Past–Present, and Future?, 36 CONN. L. REV. 125, 131-132 (2003). 
 106. BUCHANAN ET AL., supra note 79, at 12-13. 
 107. See id. 
 108. Id. at 13. 
 109. See generally Baruch et al., supra note 5, at 1055-56 (surveying PGD providers’ 
willingness to perform the technique for medical and social reasons). 
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in a way that maximizes health.  A person’s understanding of their own 
health vulnerabilities are gleaned through various channels providing both 
specific and general health information.  A person can learn directly about 
his or her own health from bouts of ill health, visits with health care 
providers, or results of medical testing.  In addition, public education plays a 
role in individual health by the dissemination of information about risks and 
benefits to health via certain activities, foods, and therapeutics.  An 
individual armed with specific and general health information can adjust 
behaviors to promote good health. 
For example, a woman with a family history of breast cancer can 
undergo a genetic test to see if she possesses of any of the genetic 
mutations associated with inherited forms of breast cancer.110  If so, she can 
take several steps to reduce and possibly avoid onset of the disease.  She 
can modify her lifestyle to include a healthier diet and more exercise, both 
shown to reduce the risk of disease onset in women with the genetic marker 
for breast cancer.111  She can consider taking a drug regimen which studies 
show can reduce the chances of developing the disease in some cases.112  
And she can opt for prophylactic surgery in which susceptible breast tissue is 
removed, thus substantially reducing her chances of developing breast 
cancer.113  A woman who knows she is highly susceptible to breast cancer 
may be super vigilant about her health in general, taking far fewer health 
risks than someone with no such predisposition. 
It is understandable that a woman whose life is affected by her genetic 
predisposition to breast cancer would want to spare her children such 
trauma.  Today such a woman could use PGD to select both male and 
female embryos that do not bear the known genetic mutation.114  How 
 
 110. NAT’L CANCER INST., NAT’L INST. OF HEALTH, U.S. DEP’T OF HEALTH & HUM. SERV., PUB 
NO. 05-4252, GENETIC TESTING FOR BREAST AND OVARIAN CANCER RISK: IT’S YOUR CHOICE 2-3 
(2005), available at www.cancer.gov/cancertopics/Genetic-Testing-for-Breast-and-Ovarian-
Cancer-Risk/pdf (last visited Feb. 3, 2009). 
 111. See A. Nkondjock et al., Diet, Lifestyle and BRCA-Related Breast Cancer Risk Among 
French Canadians, 98 BREAST CANCER RES. & TREATMENT 285, 292 (2006). 
 112. See Mary-Claire King et al., Tamoxifen and Breast Cancer Incidence Among Women 
with Inherited Mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel 
Project (NSABP-P1) Breast Cancer Prevention Trial, 286 JAMA 2251, 2255 (2001) (suggesting 
that prophylactic tamoxifen treatment may be effective for women with BRCA2 mutations, but 
not for women with BRCA1 mutations.  The study tested the efficacy of tamoxifen in reducing 
occurrences of breast cancer among cancer-free women with BRCA1 and BRCA2 mutations.). 
 113. See id. 
 114. Males who possess the genetic mutations BRCA1 or BRCA2 are at increased risk of 
developing breast cancer.  Yu Chuan Tai et al., Breast Cancer Risk Among Male BRCA1 and 
BRCA2 Mutation Carriers, 99 J. NAT’L CANCER INST. 1811, 1813 (2007); see also Science 
Daily, Breast Cancer Risk Elevated in Male BRCA Mutation Carriers, at www.sciencedaily.com/ 
releases/2007/11/071127171305.htm (last visited Feb. 3, 2009). 
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might such a decision impact on the child’s life?  At least two possible 
behavioral scenarios emerge. 
If the child is told about the orchestrated origins of their conception, he 
or she might be grateful to the parent for eliminating that particular cancer 
risk from their bloodline.  But a sense of invincibility could follow.  The child, 
or later the adult, may feel little incentive to adhere to a healthy lifestyle, 
believing that the parent has absorbed all responsibility for the child’s 
health.  Just as a person with a genetic predisposition can overemphasize 
health in their lifestyle, a person purposefully conceived to be free of the 
predisposition may be lackadaisical toward their health in general, perhaps 
increasing the risk of sporadic illness or traumatic injury.  Moreover, a 
person who ignores or downplays health maintenance could be woefully 
unprepared to cope with injury or illness, compared to a person who does 
not take good health for granted. 
Alternatively, a person born into a family whose adult members have 
suffered the devastating effects of inherited breast cancer may feel both 
relief and appreciation for their genetic good fortune.  They may have an 
enhanced sense of the importance of good health, taking measures to 
protect themselves against known health diminishers.  At least in the first 
generation of PGD use, children born without the genetic mutation will 
belong to families in which one or several members are affected by the 
cancer susceptibility gene.  Watching a loved one suffer can be a powerful 
incentive to guard one’s own good health. 
I find the latter scenario far more likely and far more consistent with our 
past experiences with breakthroughs in disease prevention.  PGD may have 
certain unique qualities, but it is not the first medical advance to offer 
parents an opportunity to protect their children against disease.  The 
introduction of childhood vaccines allows, and in some cases mandates,115 
parents to eliminate the possible onset of harmful diseases including 
smallpox,116 polio,117 measles,118 and whooping cough.119  Professor Ronald 
 
 115. See Steve P. Calandrillo, Vanishing Vaccinations: Why Are So Many Americans 
Opting Out of Vaccinating Their Children?, 37 U. MICH. J. L. REFORM 353, 358, 381-82 & 
n.199 (2004) (stating that fifty states have enacted compulsory childhood vaccination laws to 
stop the spread of preventable diseases.  “The laws require proof of certain immunizations 
prior to a child's entry into daycare or school, and provide for exclusion of children not in 
conformity.”  Nearly all states provide religious exemptions, and about a dozen now have 
philosophical opt-outs). 
 116. Smallpox, “[a]lso known as variola, [is] a highly contagious and frequently fatal viral 
disease characterized by a biphasic fever and a distinctive skin rash that left pock marks in its 
wake. . . .  The disease is caused by the variola virus.  The incubation period is about 12 days 
(range: 7 to 17 days) following exposure.  Initial symptoms include high fever, fatigue, and 
head and back aches.  A characteristic rash, most prominent on the face, arms, and legs, 
follows in 2-3 days. . . .  The majority of patients with smallpox recover, but death occurs in 
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Green makes an interesting point about the use of vaccines in his recent 
book assessing the ethics of PGD.120  In comparing vaccines (disease 
prevention) to PGD (genetic enhancement), Green observes, “[w]hen we are 
inoculated, the DNA in our white blood cells undergoes irreversible genetic 
changes, initiating the synthesis of antibodies to many viruses and bacteria.  
 
up to 30% of cases.   Smallpox is spread from one person to another by infected saliva 
droplets that expose a susceptible person having face-to-face contact with the ill person.”  
MedicineNet.com, Definition of Smallpox, at www.medterms.com/script/main/art.asp?article 
key=6328 (last visited Feb. 3, 2009). 
 117. Polio, short for poliomyelitis, “is a viral disease that can affect nerves and lead to 
paralysis. . . .  The virus spreads by direct person-to-person contact, by contact with infected 
mucus or phlegm from the nose or mouth, or by contact with infected feces.  The virus enters 
through the mouth and nose, multiplies in the throat and intestinal tract, and then is absorbed 
and spread through the blood and lymph system. . . .  Between 1840 and the 1950s, polio 
was a worldwide epidemic.  Since the development of polio vaccines, the incidence of the 
disease has been greatly reduced.  Polio has been wiped out in a number of countries.  There 
have been very few cases of polio in the Western hemisphere since the late 1970s.  Children 
in the United States are now routinely vaccinated against the disease.”  U.S. Nat’l Lib. of 
Med., MedlinePlus, Poliomyelitis, at www.nlm.nih.gov/medlineplus/ency/article/001402.htm 
(last visited Feb. 3, 2009). 
 118. Measles is caused by a highly contagious virus.  “The infection is spread by contact 
with droplets from the nose, mouth, or throat of an infected person.  For example, sneezing 
and coughing can put contaminated droplets into the air. . . .  Persons with the measles 
typically have a fever, cough, redness and irritation of the eyes (conjunctivitis), and a rash that 
spreads.  Those who have had an active measles infection or who have been vaccinated 
against the measles have immunity to the disease.  Before widespread immunization, measles 
was so common during childhood that most people became sick with the disease by age 20.  
While the number of measles cases dropped over the last several decades to virtually none in 
the U.S. and Canada, rates have started to rise again recently.”  U.S. Nat’l Lib. of Med., 
MedlinePlus, Measles, at www.nlm.nih.gov/medlineplus/ency/article/001569.htm (last visited 
Feb. 3, 2009). 
 119. Whooping cough, also known as pertussis, “is a highly contagious bacterial disease 
that causes uncontrollable, violent coughing.  The coughing can make it hard to breathe.  A 
deep ‘whooping’ sound is often heard when the patient tries to take a breath. . . .  When an 
infected person sneezes or coughs, tiny droplets containing the bacteria move through the air, 
and the disease is easily spread from person to person. . . .  Whooping cough can affect 
people of any age.  Before vaccines were widely available, the disease was most common in 
infants and young children.  Now that most children are immunized before entering school, 
the higher percentage of cases is seen among adolescents and adults.”  U.S. Nat’l Lib. of 
Med., MedlinePlus, Pertussis, at www.nlm.nih.gov/medlineplus/ency/article/001561.htm (last 
visited Feb. 3, 2009). 
 120. Ronald Green is the Eunice & Julian Cohen Professor for the Study of Ethics and 
Human Values and director of the Ethics Institute at Dartmouth College.  Dartmouth College, 
Ethics Institute, Ronald M. Green, at www.dartmouth.edu/~ethics/about/ronaldgreen.html 
(last visited Feb. 3, 2009); RONALD M. GREEN, BABIES BY DESIGN: THE ETHICS OF GENETIC 
CHOICE (2007) [hereinafter BABIES BY DESIGN]. 
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Vaccinations make us superhumans, but no one ridicules enhancements of 
this sort.”121 
Vaccines, viewed as genetic enhancements or disease prevention, have 
not affected the way the inoculated view health in general.  Knowing that 
one cannot be infected with smallpox or polio does not translate into 
recklessness or fearlessness about other health matters.  Likewise, PGD, 
viewed either as a form of genetic enhancement or disease prevention, 
would not affect the way the resulting offspring view their general health.  
Knowing that one is protected against a particular disease (inherited forms 
of breast or colon cancer, for example) does not change one’s perceived 
vulnerability, or lack thereof, toward the myriad other diseases that plague 
the human race.  While a PGD-selected adult may be less vigilant about 
certain diseases, protection against one or several genetic disorders is a 
proverbial drop in the bucket when it comes to the array of health maladies 
that lurk in any lifetime. 
PGD does shift some medical decision-making from person to parent, 
but the shift is subtle in the context of the resulting child’s (and later adult’s) 
overall health status.  Whether disease prevention occurs prenatally or 
postnatally is of little moment in the lifetime of the individual spared from 
diseases that sickened prior generations.  Allowing parents to make choices 
that avoid harm to their children seems consistent with the traditional role 
that parents have played in protecting and defending the health of their 
children.  Since disease prevention measures are best practiced sooner than 
later in the human life cycle, better we honor the shift of medical decision-
making from person to parent when deleterious genetic anomalies can be 
avoided.  Parental stewardship may require nothing less, a debatable point I 
refer to as “the expectation problem,” to which I now turn. 
C. The Expectation Problem   
Since its introduction nearly two decades ago, PGD has received its 
share of criticism from the academic ethics community whose concerns 
range from the intentional destruction of human embryos to the creation of 
a genetic overclass bred to dominate those less-genetically well endowed.122  
 
 121. GREEN, BABIES BY DESIGN, supra note 120, at 60. 
 122. Professor Janet Dolgin provides a succinct summary of the main objections to PGD in 
her article titled Method, Mediations, and the Moral Dimensions of Preimplantation Genetic 
Diagnosis.  She cites the five main moral objections to PGD as: (1) the technique involves 
embryo destruction, an impermissible act to those who adhere to the belief that personhood 
begins at conception; (2) it commodifies children by reducing their value to the sum of their 
distinct traits, rather than their personhood as a whole; (3) it is a form of eugenics because it 
allows the selection of embryos (and later persons) with favored traits and the destruction of 
embryos with disfavored traits; (4) its high cost impacts principles of distributive justice, 
because it is available only to wealthier parents, leaving less wealthy individuals more likely to 
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In the context of selection (and thereby deselection) of embryos to maximize 
the health of the resulting child, one critique dominates—the concern that a 
parent’s choice to use PGD to assure offspring health will convert into 
parental duty to do so.123  As the technique is perfected and becomes more 
widely available, social pressure will mount to form an expectation that a 
child’s well-being is served only by prenatal manipulation of the offspring’s 
health status.  This “expectation problem” is described by the President’s 
Council on Bioethics in their 2004 report, Reproduction and Responsibility, 
which warns that “[a]s the aggregate effect of parental choices reshapes 
society’s understanding of ‘normal’ or ‘acceptable’ phenotypes, parents 
might feel social pressure to undergo PGD, as many pregnant women are 
now pressured to undergo amniocentesis.”124 
The expectation problem is comprised of two dependent components—
the expectation to use PGD and the expectation to then discard embryos 
with genetic anomalies.  I label these components as dependent because 
the clinical reality is that parents who seek out PGD to detect the health of 
their embryos do so in order to implant only those that do not bear an 
unhealthy genome.125  What concerns many about the expectation problem 
is the lack of boundaries surrounding acceptable uses of the screening 
technology.  As discussed in Part III(A), the spectrum of genetic disease 
penetrance and severity is wide, admitting the possibility that an embryo with 
a low likelihood of developing a highly manageable disease could fall prey 
 
birth children with genetic anomalies; and (5) it is an affront to the disabilities community for 
its expression of rejection of physical or mental difference in society.  See Janet L. Dolgin, 
Methods, Mediations, and the Moral Dimensions of Preimplantation Genetic Diagnosis, 35 
CUMB. L. REV. 519, 522-26 (2005).  Critiques of PGD for its potential to create a genetic 
overclass worry “[w]hat the emergence of a genetic overclass will do to the idea of universal 
human dignity. . . . [T]o the extent that [young people] become ‘children of choice’ who have 
been genetically selected by their parents for certain characteristics, they may come to believe 
increasingly that their success is a matter not just of luck but of good choices and planning on 
the part of their parents, and hence something deserved.  They will look, think, act, and 
perhaps even feel differently from those who were not similarly chosen, and may come in time 
to think of themselves as different kinds of creatures.  They may, in short, feel themselves to be 
aristocrats, and unlike aristocrats of old, their claim to better birth will be rooted in nature and 
not convention.”  FRANCIS FUKUYAMA, OUR POSTHUMAN FUTURE: CONSEQUENCES OF THE 
BIOTECHNOLOGY REVOLUTION 157 (2002). 
 123. THE PRESIDENT’S COUNCIL ON BIOETHICS, REPROD. AND RESP.: THE REG. OF NEW 
BIOTECHNOLOGIES 96 (2004) (noting that parents might feel socially pressured to undergo 
PGD.  In addition to social pressure, parents might feel compelled to use PGD for financial 
reasons, to avoid having a child with debilitating and costly genetic disorder). 
 124. Id. 
 125. The use of PGD for so-called intentional diminishment, described in Vignette 3: Using 
PGD to Satisfy Parental Preferences, supra notes 22-28 and accompanying text, could be 
viewed as an exception to the general use of the technique to assure the good health and 
function of the resulting offspring. 
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to the expectation of discard once PGD is performed.  While the desire to 
avoid birthing a child with a lethal anomaly such as Tay-Sachs disease 
might strike all but the most ardent embryo defenders as morally 
acceptable, there is growing concern that parents will be pressured to 
discard embryos with mild or even benign deviations from the norm.126 
The critique that the mere presence of prenatal screening technologies 
pressures parents into rejecting “imperfect” offspring is not unique to PGD.  
In her book, The Dream of the Perfect Child, Joan Rothschild argues that all 
forms of prenatal diagnosis, from ultrasound to amniocentesis to chorionic 
villus sampling to PGD,127 create what she terms a “discourse of the perfect 
child.”128  This discourse demands that parents reject, via abortion or 
embryo discard, anything less than a perfectly healthy child.129  Professor 
 
 126. See Jason Christopher Roberts, Customizing Conception: A Survey of Preimplantation 
Genetic Diagnosis and the Resulting Social, Ethical, and Legal Dilemmas, 2002 DUKE L. & 
TECH. REV., 0012 § IV.  Roberts suggests that when multiple embryos are screened there is 
“inherent pressure to select only the most desirable traits.”  Id. While it is currently not possible 
to screen for physical and behavioral traits, there is risk that parents will select only the most 
desirable traits, leaving others to “drift randomly among the families of the underclass.”  Id. 
(quoting LEE SILVER, REMAKING EDEN: CLONING AND BEYOND IN A BRAVE NEW WORLD 225 
(1997)). 
 127. JOAN ROTHSCHILD, THE DREAM OF THE PERFECT CHILD 76-88 (2005).  The 
armamentarium of prenatal tests began to build in the late 1950s and early 1960s with the 
introduction of ultrasound into obstetric practice.  Cynthia M. Powell, The Current State of 
Prenatal Genetic Testing in the United States, in PRENATAL TESTING AND DISABILITY RIGHTS 46 
(Erik Parens & Adreinne Asch eds., 2000).  In the 1970s, physicians began to routinely offer 
their pregnant patients maternal serum screening—via a simple blood test—to measure 
biochemical markers associated with several conditions in the fetus, including neural tube 
impairments such as spina bifida and anencephaly, and Down syndrome.  Id. at 45-46.  
Today’s pregnant woman can also undergo amniocentesis and chorionic villus sampling 
(CVS) to detect fetal chromosomal abnormalities.  Id. at 44-48. 
  According to the Centers for Disease Control and Prevention (CDC), “in 2003, 67 
percent of women who had live births [in the U.S.] received ultrasound,” a steady increase 
from 47.6% in 1989.  CTRS. FOR DISEASE CONTROL & PREVENTION, U.S. DEP’T. OF HEALTH & 
HUMAN SERVS., PUB. NO. (PHS) 2005-1120, Births: Final Data for 2003, NATIONAL VITAL 
STATISTICS REPS., 1, 13 (2005).  The rate of amniocentesis for 2003 was 1.7%, a decline from 
the 3.2% reported in 1989, due in large measure to the increased use of noninvasive 
screening tests such as ultrasound and measurement of maternal serum markers.  Id. at 14.  
The use of maternal serum markers to assess fetal health, commonly referred to as a “triple 
screen,” looks for three types of biochemical markers in a pregnant woman’s blood during the 
second trimester of pregnancy.  Powell, The Current State of Prenatal Genetic Testing in the 
United States, supra, at 45-46.  Elevated and low levels of certain markers can be associated 
with certain neural tube and genetic defects, and often prompt women to follow up an 
abnormal finding with ultrasound or amniocentesis.  Id. 
 128. ROTHSCHILD, supra note 127, at 3. 
 129. See id. at 3-4, 105 (stating that the discourse of the imperfect child arises in clinical 
setting, where the parents have to decide whether to keep the pregnancy or terminate it, if the 
prenatal diagnosis unveils an imperfect child). 
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Rothschild laments the increasingly routine use of prenatal testing, which 
fuels the expectation on the part of medical personnel and society at large 
that the purpose of testing is to eliminate those with anomalies from the 
population.130  “The discourse that emerges in reproductive medicine 
characterizes the birth of a child with ‘defects’ as a tragedy, to be avoided 
by every means that science and technology can muster.”131 
The discourse of the perfect child is particularly troubling to the disability 
rights community, who view the discard of “imperfect” embryos as 
discrimination against existing persons with disabilities.  As explained by 
Professors Adrienne Asch and Erik Parens, when a child has a disability, “a 
single trait stands in for the whole, the trait obliterates the whole[]” with “no 
need to find out about the rest.”132  In the context of disabilities and prenatal 
testing, detection of a genetic disability often leads to selective abortion 
because the parents view the fetus only in terms of the disability, paying no 
regard to the many other qualities of the potential child.133  The parent sees 
the prospective child only as the disability, and this single trait enables the 
parents to justify their action.134  The abortion is ridding society of the 
disability—not of a child who, despite or possibly because of the disability, 
could lead a productive and happy life.135 
This sequence of events—prenatal diagnosis followed by embryo discard 
or selective abortion—sends a message “that disability itself, not societal 
discrimination against people with disabilities, is the problem to be 
solved.”136  Biologic elimination trumps social accommodation when the 
collective decision of prospective parents is to avoid the birth of a child with 
 
 130. See id. at 6.  Professor Rothschild writes that the promise of a “perfect baby” comes in 
the form of technology which is misunderstood “as a guarantor of perfection.”  Id.  She argues 
that while technology allows medical practitioners to cure diseases in adults, children and 
fetuses, it also serves “to discover and weed out the imperfect.”  Id. 
 131. Id. at 105. 
 132. Eric Parens & Adrienne Asch, The Disability Rights Critique of Prenatal Genetic 
Testing: Reflections and Recommendations, in PRENATAL TESTING AND DISABILITY RIGHTS 13 (Erik 
Parens & Adreinne Asch eds., 2000). 
 133. See id. at 14. 
 134. See id. at 13-14.  Asch and Parens argue that persons with disabilities are 
discriminated against because of a single trait that they bear.  Id.  Prenatal testing is a form of 
discrimination because a single trait revealed during prenatal testing can be enough to 
warrant an abortion.  Id. at 14.  Parents may choose to abort an otherwise wanted fetus 
because they see an undesirable trait, not a child as a whole.  Id. 
 135. See id. at 12-17 (Professors Parens & Asch argue that selective abortion discriminates 
against disability. With prenatal diagnosis we are trying to screen out and prevent the birth of 
children with what we perceive to be undesirable characteristics. Thus, we allow a single trait 
to “stand in for the whole” and “obliterate the whole.”). 
 136. Id. at 13. 
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disabilities.137  Why is disability itself a problem, query Asch and Parens?138  
The disability rights critique argues that disability is seen as a problem not to 
the disabled person (whose main problem is the attitudes of others toward 
disability), but rather as a diminishment to the parental experience.139  
Having a disabled child, prospective parents worry, will rob them of their 
anticipated rearing experience.140  Thus, refusing to gestate or aborting a 
disabled child is a way of preserving and upholding parental notions about 
the role that reproduction will play in their lives.141  Viewed from the 
disability rights perspective, the societal expectation problem described at 
the outset is merely a reflection of individual expectations surrounding 
reproduction. 
Understandably, the disability rights community views the expectation 
problem as gravely troubling, posing a “fear of elimination” as parents 
select against more and milder anomalies.142  But others defend the 
expected use of PGD as a valid, even required, exercise of parental 
responsibility.  Philosopher Janet Malek stakes out what she calls “the Strong 
Claim” on the use of PGD.143  “There are some situations,” she posits, “in 
which potential parents are morally required to use reproductive genetic 
technologies to reduce the likelihood that their future child will have a 
disabling condition.”144  Dr. Malek argues that acting in accordance with 
the Strong Claim maximizes the future child’s opportunities and well-being, 
 
 137. See generally Parens & Asch, supra note 132, at 12-29. 
 138. Id. at 13-15, 17-90.  In addition to noting that a single trait stands in for the whole 
when parents decide whether to have a child with a disability, Parens & Asch present their 
“parental attitude argument,” contending that disability becomes an issue when prospective 
parents allow it.  Id.  “If prospective parents imagine that disability precludes everything else 
that could be wonderful about a child, they are likely acting on misinformation and 
stereotypes.”  Id. at 17.  If parents understand that a disability is only one of a “fetus’s 
characteristics” than they can enjoy being a parent to a child with a disability without “turning 
the child into someone she is not.”  Id. at 17-18. 
 139. Id. at 13. 
 140. Id. 
 141. See id.  Professors Parens and Asch lament this parental view as “unfortunate, often 
misinformed” because they overestimate the negative aspects and underestimate the value 
and satisfaction of parenting a disabled child.  Id. 
 142. See Suzanne Holland, Selecting Against Difference: Assisted Reproduction, Disability 
and Regulation, 30 FLA. ST. U. L. REV., 401, 407-08 (2003) (noting the fear of many disabled 
people and some homosexuals that society would wish to eliminate them through prenatal 
genetic testing). 
 143. Janet Malek, Assistant Professor, Dep’t of Med. Human., Brody Sch. of Med., E. 
Carolina Univ., Presented at the Saint Louis University School of Law 20th Annual Health Law 
Symposium: Disability and the Duties of Potential Parents (Apr. 4, 2008) (PowerPoint 
presentation on file with author). 
 144. Id. 
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a special responsibility that parents are ethically obligated to undertake.145  
Because parents of existing children are obligated to reduce the likelihood 
that they will become disabled, for example by obtaining care for treatable 
diseases, the obligation to future children is no weaker.146  She 
acknowledges the disability rights critique, but finds that the sources, 
incidence, and views of disability are too diverse to be significantly impacted 
by the use of PGD.147  On balance, she concludes that the ethical demand 
for parental partiality toward their children tip the scales in favor of the 
Strong Claim in cases of disabling conditions.148 
Both the disability rights critique and the Strong Claim offer commentary 
on the expectation problem engendered by the use of PGD to assure 
embryo health.  The disability community finds the expectation problematic 
because it is based on and is calibrated to increase discrimination against 
persons with disabilities.  From this perspective, PGD is used to eliminate a 
would-be person, resulting in negative attitudes and ill-treatment of existing 
persons with disabilities.  Defenders of the Strong Claim view the 
expectation to use PGD as a moral requisite to good parenting because it 
avoids harm to a particular person—the offspring to whom parents owe a 
duty of care.  Seen from this perspective, PGD eliminates disease, thus 
fulfilling the duty of existing persons—the prospective parents. 
Is it possible to reconcile these two seemingly opposite views of the 
expected use of PGD to assure embryo health?  A place to begin may be 
with the language, and corresponding perceptions, adopted by each side.  
Instead of viewing PGD as a tool for elimination (person/disease), it should 
be seen as a means of preventing harm.  If both foes and advocates can 
agree that harm prevention is a good worth pursuing, then a dialogue can 
begin about which harms are worth preventing, and in whom the harms 
should be prevented.  As to the latter issue of who should be protected from 
harm, both sides seem to agree that existing persons, or those likely to come 
into existence, are the ones who should be protected from harm.  The 
existing person category includes persons with disabilities, prospective 
parents, and the “healthy” embryos selected for implantation.149   
 
 145. Id. 
 146. Id. 
 147. Id. 
 148. Malek, supra note 143; see also, Harris, supra note 79, at 21 (discussing what Dr. 
Malek terms “the Strong Claim”). 
 149. This categorization assumes that adherents to the disability rights critique and the 
Strong Claim do not subscribe to the view that all preimplantation embryos are existing 
persons, and thus must be implanted in order to avoid harm to the embryos themselves.  This 
view, advocated by the Catholic Church, represents an absolutist view of PGD that shuns all 
use of the technique.  See supra notes 72-78 and accompanying text.  I do not read the 
disability rights critique to say that PGD should never be used because it may lead to embryo 
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There appears nothing mutually exclusive about preventing harm to all 
three groups within the category of existing persons.  Even if one favors 
greater protection for one group, the other groups need not be made 
vulnerable to harm as in a zero-sum game.  The key to achieving equipoise 
in group harm prevention is in agreeing which harms are worth preventing.  
This determination is where the two perspectives are most likely to diverge.  
Whereas the Strong Claim may advocate for PGD to select against embryos 
that are certain or likely to experience mobility or sensory disabilities such as 
paraplegia, blindness, or deafness, the disability rights critique may argue 
these conditions do not pose harm to the individual and therefore selecting 
against them is a form of discrimination against existing persons with the 
deficits.  Even if the disability community agreed that it is better for a child to 
be born fully ambulatory with all senses intact, it would continue to worry 
about the slippery slope upon which PGD is sure to fall.  Selecting against 
severe mobility and sensory deficits could easily morph into deselecting 
embryos with extremely mild forms of the disability, such as those destined to 
be pigeon toed, color blind, or tone deaf, should these conditions ever be 
traced to a genetic cause. 
Will the ability to prevent harm to offspring that is both grave and trivial 
translate into the use of PGD to discard all but the Renaissance embryos of 
the twenty-first century?  I think the answer is no.  First, from an efficiency 
standpoint, it seems unlikely that IVF plus PGD will ever overtake the old-
fashioned way of reproducing.  The cost, time, and surgical invasion150 
required make it an unlikely rival for natural conception.  Still, the worry 
remains that the small subset of parents who do invoke PGD will ratchet up 
the indications for its use, widening the circle from individuals with a family 
history of a devastating disease to those bent on eliminating even slight 
imperfections in their family tree.  If this wider clientele does emerge, will a 
more routine use of PGD impact the way we view illness and health in our 
society, as some critics have worried?  Will our ability to select against mild 
and manageable disease translate into intolerance of those with such 
genetic disorders?  Again, I am persuaded to answer in the negative. 
The trajectory of modern medicine suggests that we will continue to 
search out causes and cures for a broad range of maladies, but that such 
 
discard.  Nothing in its concern for the lives of individuals with disabilities suggests that it 
insists on birthing infants whose life span would be a handful of years and who would suffer 
great pain throughout.  Instead, the critique reads as a plea for society to recognize the 
beneficial and productive lives that persons with disabilities lead. 
 150. The surgical invasion refers to the surgery required to extract mature eggs from a 
woman’s ovaries in order to form embryos using IVF.  PGD can only be performed on 
extracorporeal embryos, thus IVF is an essential first step to genetic testing of preimplantation 
embryos.  See COOK ET AL., supra note 3, at §9.7. 
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discoveries will have little impact on how we view those afflicted with the 
ailments.  The use of vaccines to prevent harm from disease provides a nice 
counterpart to the use of PGD to prevent harm from genetic anomaly.  
While vaccines are administered postnatally, and PGD is used prenatally, 
both aim to prevent the onset of health diminishing conditions.  Though 
PGD is still in its infancy, it appears to be traveling a path similar to that 
paved by vaccine development, initially targeting severe, life-threatening 
diseases then gradually addressing less severe conditions as more is learned 
about the technology. 
As noted previously, PGD was developed in the late 1980s to detect 
mostly lethal single-gene disorders that displayed high penetrance in 
affected families, such as Tay-Sachs disease and Huntington’s disease.151  
Today, embryologists can use PGD to detect over one hundred genetic 
conditions, some of which are nonfatal, such as familial high cholesterol, 
and others which pose a mere susceptibility to adult-onset disease, such as 
breast or colon cancer.152  This pattern repeats the development of 
vaccines, which at first were used to prevent fatal communicable diseases, 
but today are routinely administered to avoid generally mild symptoms of 
common childhood infections. 
The first successful vaccination was created by Edward Jenner in 1796 
to combat smallpox, a contagious disease that had plagued humankind for 
centuries.153  A vaccination for yellow fever followed in 1937, and the well-
known polio vaccine was introduced in a large scale trial in 1954.154  The 
President of the March of Dimes, Basil O’Connor, said of the polio vaccine 
at its introduction: 
I have just figured out that during the coming summer, thirty or forty 
thousand children will get polio.  About fifteen thousand of them will be 
paralyzed and more than a thousand will die.  If we have the capacity to 
prevent this, we have a social responsibility . . . we are supported by the 
 
 151. See supra notes 50-54 and accompanying text. 
 152. Johns Hopkins U., The Genetics & Pub. Pol’y Ctr., Issue Brief: Preimplantation 
Genetic Diagnosis (Feb. 27, 2006), at http://www.dnapolicy.org/policy.issue.php?action= 
detail&issuebrief_id=7 (last visited Feb. 3, 2009). 
 153. Smithsonian, Nat’l Museum Am. Hist., Whatever Happened to Polio?: Two Vaccines, 
at http://americanhistory.si.edu/polio/virusvaccine/vacraces.htm (last visited Feb. 3, 2009) 
[hereinafter Whatever Happened to Polio?]; see generally Stefan Riedel, Edward Jenner and 
the History of Smallpox and Vaccination, 18 PROC. (BAYLOR UNIV. MED. CENT.) 21 passim 
(2005), at www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1200696 (last visited Feb. 3, 
2009) (describing the history of smallpox and its role in the development of the field of 
immunology). 
 154. Whatever Happened to Polio?, supra note 153. 
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people and it is our duty to save lives no matter how many difficulties may 
be involved.155   
Perhaps Mr. O’Connor expressed the first iteration of the Strong Claim 
by framing the polio vaccine in terms of duty, but would he have been as 
strong an advocate for inoculating infants against a less deadly disease?  If 
we have the capacity to prevent disease through vaccination, do we have a 
social responsibility (duty) to do so?  American pediatricians seem to answer 
in the affirmative, in the form of their recommendations to parents regarding 
childhood vaccinations.  Today the American Academy of Pediatrics 
recommends that children be vaccinated against fifteen diseases, some of 
which overwhelmingly produce only mild symptoms in their host.156  For 
example, the vaccination for chicken pox was introduced in the U.S. in 
1995, and is now widely used despite the medical fact that the disease is 
generally mild and short-lived in the vast majority of those affected.157  But 
its severity in a small number of infected individuals supports its use as a 
public health matter.158 
In terms of the expectation problem, we should query whether the 
widespread, although not universal, use of childhood vaccines has changed 
the way we view children and adults who manifest the targeted disease.  
Epidemiologic data suggests that over ninety percent of children old enough 
to receive vaccinations do receive the inoculations, leaving around ten 
percent of the population voluntarily or inadvertently unvaccinated.159  As a 
result of either vaccine ineffectiveness, or the exposure of unvaccinated 
 
 155. Id. (quoting Basil O’Connor, President of March of Dimes, 1954). 
 156. CTRS. FOR DISEASE CONTROL & PREVENTION, RECOMMENDED IMMUNIZATION SCHEDULE 
FOR PERSONS AGED 0-6 YEARS—UNITED STATES: 2008, available at www.cdc.gov/vaccines/recs/ 
schedules/downloads/child/2008/08_0-6yrs_schedule_pr.pdf (last visited Feb. 3, 2009). 
 157. See generally CTRS. FOR DISEASE CONTROL & PREVENTION, CHICKEN POX VACCINE: 
WHAT YOU NEED TO KNOW, available at www.cdc.gov/vaccines/pubs/vis/downloads/vis-
varicella.pdf (last visited Feb. 3, 2009) (“Chickenpox (also called varicella) is a common 
childhood disease.  It is usually mild, but it can be serious, especially in young infants and 
adults.  It causes a rash, itching, fever, and tiredness.  It can lead to severe skin infection, 
scars, pneumonia, brain damage, or death.  The chickenpox virus can be spread from person 
to person through the air, or by contact with fluid from chickenpox blisters. . . . Before the 
vaccine, about 11,000 people were hospitalized for chickenpox each year in the United 
States.  Before the vaccine, about 100 people died each year as a result of chickenpox in the 
United States.”). 
 158. Id.; see also U.S. Nat’l Libr. of Med., Medline Plus, Chickenpox, at www.nlm.nih.gov/ 
medlineplus/ency/article/001592.htm (last visited Feb. 3, 2009). 
 159. See Jennifer Steinhauer, Rising Public Health Risk Seen as More Parents Reject 
Vaccines, N.Y. TIMES, Mar. 21, 2008, at A1 (explaining that most unvaccinated children in the 
U.S. are parented by “vaccine skeptics[,]” parents who seek exemption from state child 
vaccination laws out of a personal belief that vaccines are either dangerous or unnecessary). 
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individuals to the particular viruses, outbreaks do periodically occur.160  
Loosely applying the disability rights critique to these incidents of (largely) 
preventable diseases, we would expect to see widespread discrimination 
against individuals (or their parents) whose voluntary refusal to be 
vaccinated caused their disease syndrome.  That is, if an individual has the 
opportunity to prevent disease, then declines such opportunity, that 
individual should be derided once the disease manifests for failing to protect 
herself and possibly her community from harm. 
Instead of shunning “vaccines deviants,” society appears to have 
accepted them and accommodated their difference.  For example, several 
pediatric practices advertise their willingness to work with vaccine-adverse 
parents, permitting them to sign an “informed refusal” form declining 
vaccinations on behalf of their children.161  Also, a number of states have 
enacted broad exemptions to their vaccine mandates, allowing parents to 
opt out of required inoculations so long as they agree to keep their children 
out of school during known outbreaks.162 While the presence of 
preventable—and communicable—disease is concerning for the 
commonweal, it has not wrought isolation, denial of treatment, or 
discrimination against those who choose to live outside the bounds of 
accepted medical practice.  Being different, even “imperfect” from a 
disease-resistance perspective, has not produced widespread social harm to 
affected populations. 
The take away message from the vaccine experience may be that the 
ability to prevent disease does not necessarily translate into discrimination 
against those who manifest the disease.  Shifting back to PGD, there is 
reason to believe that this observation will hold true for disease prevention 
in the form of embryo selection.  Allowing parents to choose to birth a child 
free of known genetic disorders—even those associated with mild 
symptomology or asymptomatic carrier status—should have little or no 
impact on the treatment of living or to-be-born individuals who express 
those genetic anomalies.  Alternatively, permitting parents to forgo PGD and 
risk birthing a child with genetic anomalies, while frowned upon as a breach 
 
 160. Id. (describing recent outbreaks of measles, mumps and pertussis). 
 161. For example, Dr. Robert Sears, a pediatrician and author of THE VACCINE BOOK 
(2007), describes himself as a “vaccine-friendly” practitioner, meaning he is willing to accept 
patients in his practice that wish to delay or decline vaccinations for their children.  His website 
compiles and lists other “vaccine friendly” pediatricians.  See AskDrSears.com, What is a 
Vaccine-Friendly Doctor?, at www.askdrsears.com/thevaccinebook/Vaccine_Friendly_ 
Doctors.asp (last visited Feb. 3, 2009). 
 162. Id.  But see Calandrillo, supra note 115 (expressing concern over growing use of 
vaccine exemptions and recommending greater scrutiny of exemption requests).  See Ctrs. for 
Disease Control & Prevention, Nat’l. Vaccine Program Office: Immunization Laws, at 
www.dhhs.gov/nvpo/law.htm (last updated Feb. 3, 2009). 
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of parental duty by the Strong Claim, should likewise have no impact on 
society’s perception of that individual’s worth. Disease prevention 
technologies should be celebrated as a collective benefit when they 
succeed, but their failures should never rest on the shoulders of any affected 
individual. 
In sum, it is likely that PGD will continue to gain audience as its ability to 
reveal the embryonic genome improves.  At the same time, it seems equally 
unlikely that PGD will be a routine part of reproduction, as its cost and risk 
barriers make it unattractive to most of the world’s prospective parents.  Still, 
for the subset that wishes to screen and choose among their early embryos, 
the expectation problem will present.  The expectation that parents should 
routinely use PGD will likely impact only those parents who are already 
predisposed to accessing prenatal genetic technologies.  For these 
reprotech-inclined parents, PGD is the latest entry on the ART continuum 
that has been in development for over three decades.  This group may 
regard PGD as a “must have” because it expedites the delivery of genetic 
information and eliminates the abortion dilemma that accompanies other 
forms of prenatal genetic testing.  But the idea of a universal expectation to 
use PGD seems clinically unrealistic.  Mother Nature is a far more 
compelling, efficient, and successful alternative to technically-assisted 
procreation. 
As for the second part of the expectation problem—that once PGD is 
used it will result in deselection of embryos for milder and more benign 
conditions—this is likely to be the case.  PGD, like other forms of disease 
prevention, will begin by tackling life-threatening conditions and gradually 
expand to address less serious, albeit life-affecting, syndromes.  Will this 
incremental expansion change the way we view disease or those with 
disease in our society?  I think not.  We will continue to seek out cures and 
treatments for diseases grave and trivial because those who aspire for 
greater health in our society demand and deserve nothing less. 
Instead of fostering discrimination against those with lesser health, 
advances in the treatment and prevention of serious diseases may instead 
yield, as a byproduct, therapies useful for treating less devastating illness.  A 
modern day example of such fortuity can be found in the research 
surrounding smallpox.  We recently learned that after centuries of work to 
combat, and virtually rid the world of smallpox, a drug used for this deadly 
disease may also be useful in treating a far less serious, though annoying, 
health scourge—the common cold.  In May 2008, scientists announced the 
successful application of a smallpox drug to protect against adenovirus, 
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a.k.a. the common cold, in animal studies.163  Such is a common trajectory 
in medical research— with a destination in mind, researchers stay alert to 
useful detours along the way. 
IV.  CONCLUSION 
Genetic technologies have and will continue to change the way we think 
about our own health and that of our children.  The ability to select or 
discard early embryos on the basis of genetic health empowers parents to 
make earlier and more profound medical decisions on behalf of their 
offspring, possibly disrupting long held views about an individual’s capacity 
to control his or her own health.  PGD, with its increased sensitivity to detect 
milder and later-onset diseases, actively shifts decision-making about health 
from the affected person to the controlling parent, while tempting users to 
eliminate even slight imperfections in their offspring.  While worries abound 
that PGD will promote recklessness toward health in children spared of 
familial diseases, and disdain for those who do manifest genetic anomalies, 
nothing in our past treatment of sickness and health suggests such a future. 
The path of our plodding journey to improve human health was recently 
described by Harvard Professor of Psychology Steven Pinker in response to 
concerns that advances in technology will rob us of our basic human 
dignity. “The reality is that biomedical research[,]” Professor Pinker 
observed, “is a Sisyphean struggle to eke small increments in health from a 
staggeringly complex, entropy-beset human body.  It is not, and probably 
never will be, a runaway train.”164  While some may yearn for PGD to forge 
full-steam ahead to reveal more and more about the early human genome, 
thus enabling greater micromanagement of our genetic offspring, what we 
really should expect are baby steps in this neophyte technology whose own 
life cycle will surely long outlast each of our own. 
 
 
 163. See Smallpox Drug May Protect Against Common Cold, U.S. NEWS & WORLD REP., 
May 20, 2008, at http://health.usnews.com/articles/health/healthday/2008/05/20/smallpox-
drug-may-protect-against--common-cold.html (last visited Feb. 3, 2009). 
 164. Steven Pinker, The Stupidity of Dignity, NEW REPUBLIC, May 28, 2008, at 28, 31. 
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